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Dong Il Lee 
UNDERSTANDING THE INTEGRATED PATHOPHYSIOLOGICAL ROLE OF A 
MOONLIGHTING PROTEIN IN LUNG DEVELOPMENT 
 
Sensing, integrating, and relaying signals from the environment through proteins, 
metabolites, and lipids to the lung are critical for proper development. Moonlighting 
proteins, such as AIMP1, are a unique subset that serves at least two independent 
physiological functions. Encoded by gene AIMP1, AIMP1 has two known functions: (1) 
C-terminus EMAP II domain of full-length AIMP1 can be secreted out of the cell to 
chemoattract myeloid cells; (2) intracellular full-length protein interacts with tRNA 
synthetases in protein translation. However, despite the linkage of protein expression 
levels of with several lung pathologies such as bronchopulmonary dysplasia (BPD), 
effectively targeting the protein encoded by AIMP1 has been a challenge due to poorly 
understood mechanisms. 
This thesis explores physiological, signaling, and immunological moonlighting 
mechanisms of first, the extracellular EMAP II then the intracellular AIMP1. 
Experiments utilize both in vitro and in vivo models, including a murine model of BPD 
and Cre-mediated exon-deletion knockout. Experimental results provide evidence that in 
the BPD model, EMAP II levels are elevated and sustained – first in bronchial epithelial 
cells then in macrophages. Mice exposed to sustained and elevated EMAP II protein 
levels resemble the BPD phenotype while neutralization partially rescued the phenotype, 
implying EMAP II as a potential therapeutic target against BPD. Results from studies 
exploring EMAP II’s signaling mechanism identify transient stimulation of JAK-STAT3 
phosphorylation, commonly found in inflammation-resolving macrophages. In contrast, it 
induces unique transcriptional changes that are reversible both by JAK-STAT inhibitor 
and siRNA-mediated knockdown of Stat3.  
Studies using AIMP1 knockout mouse reveal a novel function for the intracellular 
AIMP1. AIMP1 knockout mice exhibited neonatal lethality with a respiratory distress 
phenotype, decreased type I alveolar cell expression, and disorganized bronchial 
epithelium, suggesting a role in lung maturation. In vitro experiments suggest that a 
 viii 
portion of AIMP1 residing in the cell’s membrane interacts with various 
phosphatidylinositols and contributes toward F-actin deposition and assembly.  
Data from these experimental studies provide insight into how the various 
functions of the promiscuous AIMP1 gene affect lung development. These studies 
exemplify not only characterize novel moonlighting mechanisms of AIMP1, but also 
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Chapter 1: Introduction 
In mammals, lungs primarily serve to exchange oxygen from the external 
environment with metabolically generated carbon dioxide from the cardiovascular 
system. It accomplishes this function through a complex, paired structure of branched 
airways (i.e., the bronchiolar tree) and specialized spherical-like, air-blood gas 
exchanging units (i.e., alveoli). The conducting branched airways conduct, filter, and 
warm the air from the external environment into the alveoli where it facilitates the 
exchange of gas. A network of proteins, lipids, and metabolites spatiotemporally merge 
to differentiate the primordial anterior foregut endoderm into the highly specialized lung.   
Activation and de-activation of the signaling networks regulates the progression 
of the five morphological stages of lung development: embryonic, pseudoglandular, 
canalicular, saccular and alveolar (Figure 1.1).  
 
 
Figure 1.1. Schematic depicting the corollative timeline of lung development in both humans 
and mice (Adapted from Schwarz and Cleaver, 2009).  
Throughout the stages, the networks elicit the heterogeneous cellular population of the 
lung to form coordinated complexes of transcription factors that specify lung-specifc 
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gene expression and development. Starting in the embryonic and pseudoglandular stages, 
a lung bud begins to form into the bronchial tree and the first few generations of alveolar 
sacs at which point marks the beginning of the canalicular stage. Terminal branches 
develop and narrow allowing for epithelial-mesenchymal sacs to mature into alveoli 
within the latter three stages. Branching morphogenesis and the formation of most of the 
distal airways occur during the canalicular stage. The formation of morphogenesis 
signifies the completion of the majority of the lung structure and the beginning of the 
saccular and alveolar stages. The saccular and alveolar stages are a vulnerable time 
period when perturbations can alter and limit the growth and maturation of functional 
gas-exchanging alveolar units. A prominent perturbation to proper lung development is 
preterm birth. 
Preterm births are born during the vulnerable saccular and alveolar stages, even as 
early as 23 weeks of gestation in humans or 17.5 days in mice. The lungs of the preterm 
or prematurely born infant do not contain adequate number of mature alveoli to match 
their body’s requirement of oxygen. This causes a requirement of both oxygen 
supplementation for the preterm infant with incompletely formed alveoli and surfactants 
as part of their standard of care. Although the supplementation is life preserving, it can 
lead to bronchopulmonary dysplasia (BPD), a chronic lung disease and major morbidity 
of the extremely preterm infants. 
 
1.1 Research Motivation 
The problem originally motivating this research lies in the need for a therapeutic 
target against bronchopulmonary dysplasia (BPD). The oxygen supplementation of 
preterm infants induces a strong pulmonary inflammatory response. Through a series of 
signaling events gone awry, chronic inflammation is central to the perinatal, multi-
factorial pathogenesis of BPD by limiting the structural integrity and maturation of 
potential gas-exchanging alveoli including its vasculature. The therapeutic target thus 
would also need to be directed against the chronic inflammation.  
Clinically, in addition to the standard of care, immunosuppressants such as 
antenatal steroids are administered to preterm infants in an attempt to curb the 
inflammation. Immunosuppressants are effective in brief intervals at low doses. 
 3 
However, either long-term usage or high dosages associate with adverse effects such as 
neurological disorders. Inhibiting other prominent inflammatory mediators such as tumor 
necrosis alpha in sepsis-induced inflammation showed little improvement in survival 
rates of humans whereas in murine models, only a few features of BPD improved. This 
suggests a need for either an alternative strategy to target inflammation or a target that is 
upstream of the prominent inflammatory mediators to limit the pathogenesis of BPD.  
An alternative strategy is to regulate the recruitment of myeloid cells that increase 
inflammation. Some of the protein factors that regulate the recruitment have at least two 
independent, physiological roles, which are called moonlighting proteins. Increased 
levels of the moonlighting protein Endothelial Monocyte Activating Polypeptide II 
(EMAP II) and its precursor protein Aminoacyl tRNA Multisynthetase Interacting 
Polypeptide 1 (AIMP1) has been linked to several lung pathologies. Encoded by the gene 
AIMP1, AIMP1 protein has two known functions: (1) chemoattracting of myeloid cells 
by its C-terminus EMAP II domain of full length AIMP1, which is cleaved and secreted 
out of the cell; (2) enhancing protein translation by interacting its full-length intracellular 
self with tRNA synthetases. Previously, the Schwarz laboratory, among others, linked 
increased protein levels of Endothelial Monocyte Activating Polypeptide II (EMAP II) 
with BPD. Additional evidence shows that EMAP II limits vessel formation as an anti-
angiogenic factor during lung development. This presents EMAP II as a potential 
therapeutic target against BPD pathogenesis. However, effective targeting of the 
pathogenic roles of EMAP II requires a better understanding of its mechanisms in lung 
development, which are incomplete. The mechanisms of the protein encoded by gene 
AIMP1 discussed in this thesis are needed as part of the evaluation for a potential 
therapeutic target against BPD.  
 
1.2 Research Objectives and Aims 
The overall objective of the research in this thesis is not only to present newly 
found moonlighting mechanisms of the AIMP1-encoded protein applied to lung 
development but also to demonstrate their effectiveness in the pathogenesis of BPD. The 
understanding of the mechanisms will enable effective targeting of the protein in future 
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clinical scenarios. The objective is achieved through a breakdown of smaller aims that are 
noted in the following. 
Before the first main objective could be addressed, an offshoot, minor aim of the 
primary objective arose from the need to create a reproducible, quantitative tool for 
assessing messenger RNA (mRNA) expression in lung development. Guidelines to 
perform quantitative polymerase chain reaction (qPCR) were validated for each step of 
mRNA gene expression analysis, including, but not limited to, lung sample harvesting, 
isolation, integrity, and purity of RNA, amplicon size, and data normalization. The tool is 
important not only technically but also reconciled a conflicting result among individual 
laboratories; it is used throughout the entirety of the thesis when applicable. 
 The first aim is to study the molecular and physiological mechanisms of EMAP II 
during the pathogenesis of BPD. The hypothesis of this aim is that EMAP II would 
promote an inflammatory state through recruitment of macrophages during the 
pathological formation of BPD. Testing of this aim includes the usage of three neonatal 
murine models: (a) BPD (hyperoxia-induced), (b) delivery of recombinant EMAP II, and 
(c) BPD with neutralizing EMAP II antibody treatments. In the murine models, the 
following key questions are addressed in the pathogenesis of BPD: (1) What happens to 
protein expression of EMAP II during the pathogenesis? (2) When is EMAP II 
expressed? (3) What cell types express EMAP II? (3) What cellular impact does 
sustained EMAP II have on the pathogenesis? (4) What is the impact of the sustained 
EMAP II on the physiology of the lung? (5) Can the effects of sustained EMAP II be 
reversed i.e., neutralized? 
The second aim is to determine the molecular and signaling mechanisms in the 
macrophages that were recruited in response to EMAP II.  The hypothesis of the second 
aim is that EMAP II polarizes the recruited macrophages toward a pro-inflammatory 
state. Experiments for this aim utilize thioglycollate-elicited peritoneal macrophages, a 
partially activated population. In this aim, known pro-inflammatory M1 mRNA gene 
expression and activation of transcription factors are measured in macrophages exposed 
to EMAP II compared to those not exposed, i.e. control. 
 The third and final aim is to study the role of the intracellular AIMP1 in lung 
development. This aim is to completely characterize the other potential moonlighting 
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functions of the AIMP1-encoded protein, starting with the intracellular full-length form 
that is incompletely understood. This may be in part because there has not been a report 
of a complete knockout mouse of AIMP1 until the generation of one in this thesis. 
Schwarz and others showed that at the cellular level, part of AIMP1 is expressed at the 
cell surface and at the tissue level, the epithelial-mesenchymal interface of the lung. The 
hypothesis of this aim is that cell-surface AIMP1 mediates the organization of the 
epithelium. The testing of the hypothesis is performed in vivo by comparing the lungs of 
knockout mice to characterize the physiological roles of AIMP1 while in vitro 
biochemical and molecular approaches to identify the localization and potential 
molecular interactions of AIMP1. 
 
1.3 Thesis Background Along with Related Works 
There are several important topics related to the moonlighting AIMP1-encoded 
protein and lung development discussed in this thesis: (1) animal models of lung 
development and BPD; (2) moonlighting properties; and (3) myeloid cells. The following 
subsections discuss the background and work done by other researchers that is 
particularly relevant to this research. 
 
1.3.1 Strengths in Murine Models of Lung Development and Pathophysiology 
The five stages of lung development have been well established through visual 
analysis of structural changes that occur in both human and non-human mammalian 
models over time. Without routinely accessible human lung samples, animal models have 
been invaluable to study not only lung development but also the etiology of BPD 
pathophysiology. In particular, non-diseased lungs to compare with the diseased lungs are 
difficult to acquire since samples are generally collected at the time of death. Thus 
molecular mechanisms and the refinement of key biological questions can be more easily 
addressed using animal models, and in this thesis, the mouse. 
Murine, compared to other animal, models offer several advantages: a short life 
cycle combined with high fertility rates, increased sample size, readily available and 
validated biological tools such as antibodies and gene manipulation, and ease of 
husbandry. The lung development in the mouse parallels the development in the humans 
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with differences in duration of the stage and gestational age. In the mouse, the 5 stages 
are as follows: (1) embryonic (embryonic days 9.0 to about 12.5, denoted as E9.0 to 
E12.5); (2) pseudoglandular (about E12.5 to E16.5); (3) canalicular (E16.5 – E17.5); (4) 
saccular (E17.5 – Postnatal Day 5, PN5); (5) alveolar (PN5 – maturity)3. Of note, the 
saccular stage prepares the lung for extrauterine, perinatal life. In this stage, terminal 
airways deriving from bronchioles dilate and vascularize while the production of 
surfactant is initiated. Surfactant, a lipoprotein complex, reduces surface tension within 
the forming, maturing alveoli, and in effect, enhances their opening during inhalation; 
without sufficient amounts of surfactant, respiratory distress forms. 
A notable difference between mice and human lung development occurs in the 
saccular stage. On the one hand, mice are born at term during the saccular stage, which in 
mice begins in utero and continues through birth at term until PN5. On the other hand, 
human infants born during the stage are premature. It is important to note that the mice 
born in the saccular stage have adequate surfactant and without either respiratory distress 
or morbidity issues. The human preterm infants born during the saccular stage are at high 
risk of developing respiratory distress due to their underdeveloped lungs. Since lungs of 
neonatal mice contain adequate surfactant but human preterm infants do not, this can be 
somewhat considered akin to antenatal steroids delivered to the human preterm neonate 
(reference). Thus mice are useful models of normal and pre-term birth. This will be 
important later in the discussion of BPD pathogenesis. 
 
1.3.2 Signaling mechanisms and functional changes during BPD pathogenesis 
Changes in the environment are conveyed through signaling networks of proteins, 
metabolites, and lipids. Broadly stated, extracellularly secreted proteins induce 
autocrinic, endocrinic, and paracrinic signaling to spatiotemporally regulate intracellular 
events. The extracellular secreted factors initiate various signaling processes through 
intracellular protein-protein interactions and the phospholipids. This enables progenitor 
cells to differentiate into the heterogeneous cell population that make up the lung. 
Mechanical forces during the pseudoglandular stage are one of the earliest changes in the 
environment of the lung, which activate BMP signaling. Then, several signaling 
pathways coordinate lung specification by gene expression changes controlled by 
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transcription factors. Among them, Wnt/Beta-catenin, BMP, and Shh signaling pathways 
are essential for lung development and fate specification4. Recently, JAK/STAT 
signaling, highly context specific has joined the signaling pathways that are necessary to 
initiate alveolar formation and to promote alveolar differentiation5. 
Within a single alveolar sac, there exists a multi-cellular population: Type I and II 
epithelial cells, endothelial cells, and macrophages. The epithelial cell organization is 
comprised of both Type I cells that cover roughly 95%-97% of the alveoli’s surface area 
and responsible for gas exchange, and Type II cells that synthesize surfactants. It was 
long-standing dogma that in lung development, a single progenitor population yielded 
Type II cells, which in turn were precursors for Type I in a relatively linear fashion. 
However, a recent study proposed a revised model in which a bipotent progenitor cell 
population, emerging around murine E17.5, i.e. canalicular to saccular stage transition, 
differentiates independently into Type I and Type II cells, or pneumocytes, in both 
development and injury6. Cells whose fate is to become Type I cells begin to express 
podoplanin (Pdpn or T1alpha) during pre-sacculation but acquire aquaporin 5 (Aqp5) 
toward matured late-sacculation; cells whose fate is to become Type II cells express 
surfactant protein C (Sftpc) throughout the maturation process, but only the transcription 
factor Nkx2.1 in pre-sacculation. Whereas Aqp5+ Type I cells largely mediate the direct 
gas-exchange of oxygen and carbon dioxide and contain relatively no organelles, Sftpc+ 
Type II cells synthesize surfactants either de novo primarily from lipids, such as 
phosphatidylcholine or from an acylation/reacylation pathway generated from the 
airspace7. As found evident by knockout mouse models, insufficient timing or magnitude 
of differentiating cells result in a lethal phenotype. Similar deficiencies are present in the 
BPD preterm lung.  
Proper regulation of the signaling pathways results in a fully differentiated lung 
that can expand and contract to enable breathing. Fetal respiratory movement has been 
observed as early as E14.5 in the mouse8. Upon extrauterine delivery, the lung undergoes 
physiological transition in preparation for its first contact with air and breath. The lung’s 
airspace clears their fluids through active transport of chloride against a lower protein 
concentration gradient. Further endocrinic adaptions occur to activate Na+/K+ ATPase 
channels, and Type II cells primarily mediate these effects9. 
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The pulmonary structure has been better described than pulmonary function 
throughout development. Technological tools are not yet advanced enough to directly test 
pulmonary function throughout neonatal development. Thus what is known about the 
function is generally inferred from morphological changes. By extension, how pulmonary 
function is affected by disrupting lung development is poorly understood. A useful 
determinant of pulmonary function to is to measure compliance. Compliance refers to 
change in lung volume for a given change in pressure and increases proportionally to the 
amount of matured alveoli, thereby can increase until alveologenesis has completed10,11. 
In light of this limitation, in this thesis, similar to clinical studies, we study how structural 
deformities impact later pulmonary function, as seen later in Chapter 3.  
 
1.3.3 Inflammation disrupting alveolarization in the pathogenesis of BPD  
Disruption in the differentiation of any one of the cell types that make up the 
alveoli is sufficient to disrupt the process of alveolarization as a whole. The disruption 
can be found in the BPD lung, where it also is defined by arrested alveolar development, 
inflammation although less so than the older counterpart, and airways being spared1. 
These clinical features are referred to as ‘new BPD’ in contrast to ‘old BPD’ that was 
defined by structural injuries to the alveoli (Figure 1.2). In this thesis, BPD refers to the 





Figure 1.2. Diagram comparing ‘old’ to ‘new’ BPD over the 5 stages of lung development1. 
 
Although overall morbidity due to prematurity has decreased, premature birth 
remains a leading contributor toward neonatal mortality within the United States12-14. 
Primary prevention is thus still elusive while molecular and physiological mechanisms 
are lacking. Clinically, patients with BPD have a need for supplemental oxygen for at 
least 28 days that is determined at 36 weeks of postmenstrual age15,16. Of those patients, 
nearly 4 in 5 preterm BPD patients have secondary pulmonary hypertension (PH), which 
may also have higher odds of mortality (reference). Therapies for BPD neonates 
including those with PH are limited. 
As previously stated, inflammation is central to the pathogenesis of BPD. 
Deregulated signaling pathways perpetuate the inflammation and recruitment of myeloid 
cells (e.g. neutrophils, monocytes/macrophages). The spatiotemporal signaling 
mechanisms that regulate lung development and pathogenesis also regulate macrophage 
activation. Macrophages maintain tissue homeostasis of the lung in waves of signaling 
networks, and disruption of this timing is frequently disrupted in pathogenesis. The 
regulation of macrophage activation, i.e., polarization, is crucial to maintain homeostasis 
yet is incompletely characterized, particularly in neonatal diseases.  
Macrophage polarization refers to the degree of macrophage activation at any 
given time and space in a continuous, simplistic spectrum, inflammatory M1 at one end 
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and inflammatory-resolving or suppressing M2 at the other end17. Very polarized 
macrophages express specific genes that are minimally expressed or absent in their 
counterpart. On the one hand, in M1 macrophages, pro-inflammatory genes such as Tnf, 
Il1b, or iNos/Nos2, are highly expressed but almost absent in M2 macrophages. On the 
other hand, M2 macrophages express specific genes such as Arg1 or Il10 found 
minimally in M1. The JAK/STAT signaling pathway is important in not only lung 
development but also in macrophage polarization – it initiates the dampening pro-
inflammatory transcription yet promotes anti-inflammatory transcription (Figure 1.4)17.  
 
 
Figure 1.3. Model illustrating signaling factors that regulate the dichotomous extremes of 
macrophage polarization in bactericidal response. Simplified diagram depicting signaling pathways 
used by macrophages to cue pro-inflammatory (M1) or anti-inflammatory (M2) responses2. 
 
Generally speaking, STAT1 is commonly activated in macrophages soon after 
their encounter with a pathogenic insult, such as hyperoxia in BPD. Following STAT1 is 
NF-kB, and then a resolve by activation of STAT3. It is important to note that much of 
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what is known about macrophage activation comes from other contexts such as bacterial 
infection. What is known in context of lung development and BPD pathogenesis is very 
limited: anti-inflammatory monocytes, closely resembling M2 protect the lung from 
hyperoxia-induced BPD. 
Many clinical studies utilizing various compounds to prevent BPD pathogenesis 
have been largely marginally effective18. Mechanisms of BPD pathogenesis remain yet 
unknown, especially due to an incomplete insight of how the transitions between stages 
of lung development are regulated. Many targets against BPD pathogenesis have been 
proposed but heavily have only been studied by relying on only either morphology or 
molecular biology. This presents a need to study the lung development comparatively to 
its pathogenic counterpart that encompasses an integrative approach through molecular, 
cellular, and physiological approaches. The evaluation of potential therapeutic targets 
used rescue approaches that resulted in the rescue of only certain BPD outcomes. This 
leaves a large scope for improvement in not only how the potential of BPD therapeutic 
targets are evaluated but also choosing a better target. 
 
1.3.4 Moonlighting proteins including AIMP1 
Several factors mediate the recruitment of macrophages in BPD, of which are 
moonlighting proteins. In 1999, Constance J. Jeffrey coined the term ‘moonlighting 
protein’ to describe a subset of proteins that have at least two independent, physiological 
functions which can occur simultaneously not due to either gene fusion, RNA splicing 
variation, or pleiotropic effects19. Recent technological advances in comprehensive 
proteomic and genetic studies have revealed hundreds of the proteins that moonlight in 
both homeostasis and pathogenesis20. For example, high‐mobility group box‐1 (HMGB1) 
can function as a DNA chaperones in the nucleus but also as both an intercellular-
mediating cytokine and inflammatory mediator. Another example, and linked to HMGB1 
is signal transducer and activator of transcription 3 (STAT3). It typically functions as a 
transcription factor of gene expression in the nucleus, but a portion of cellular STAT3 
that is modified by serine phosphorylation at amino acid 727 functions as mediator of 
oxidative phosphorylation. This implicates the importance to comprehensively 
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investigate moonlighting mechanisms of a protein; in the context of lung development 
and pathology, moonlighting mechanisms have not been studied. 
 
1.3.4.1 AIMP1-encoded protein, extracellular, secreted EMAP II 
This thesis focuses on the moonlighting protein encoded by gene AIMP1. The 
ubiquitous gene AIMP1 encodes for a 34 kilodalton (kDa) protein Aminoacyl tRNA 
Synthetase Complex Interacting Multifunctional Protein 1 (AIMP1). AIMP1 in humans 
has two isoforms. One isoform generates a longer 336 amino acid form while the other a 
312 amino acid protein that is conserved in mice has been linked to several 
cardiopulmonary pathologies21-25. In this thesis, AIMP1 refers to the intracellular 34-kDa 
protein. While many phenotypic effects of AIMP1 have been described, their 
mechanisms are not well understood. This underlies an importance of understanding the 
protein, particularly in context of recent discoveries that pose moonlighting properties. 
This thesis studies the undiscovered functions and mechanisms of the role of AIMP1 in 
lung development and pathogenesis. 
  From the full length AIMP1, the 23 kDa, C-terminal Endothelial Monocyte-
Activating Polypeptide II (EMAP II) portion is cleaved and secreted, to which many 
functions have been attributed24-31. In this thesis, EMAP II refers to the secreted 
extracellular portion. EMAP II was originally described to recruit myeloid cells32. During 
normal lung development, its levels are transient, negatively correlating with pulmonary 
microvascularization; namely, it increases upon canalicular stage yet decreases during 
saccular and into alveolar stages29,33. It serves an anti-angiogenic function of endothelial 
cells by inhibiting VEGFR2 phosphorylation and integrin activation. Contrary to normal 
lung development, in premature lung disease, i.e. bronchopulmonary dysplasia (BPD), its 
levels are increased compared to age-matched controls34. How the increased amounts of 
EMAP II affect and the mechanisms that it plays during BPD is unclear. BPD will be 
discussed in further detail in 1.4. 
 
1.3.4.2 Unknown role of intracellular AIMP1 
AIMP1 is one of the three proteins that collectively scaffold nine tRNA 
synthetases and altogether make up the multi-synthetase complex (MSC). It is the only 
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one of the protein scaffolds that is expressed in all organisms although in varying 
levels35. Various in silico and structural analysis and crystal structure analysis show that 
AIMP1 comprises 3 domains: (1) N-terminal leucine zipper; (2) intrinsically disordered 
region; (3) the aforementioned EMAP II (Figure 1.3). Although its structure has been 
partly characterized, the knowledge of the function of the intracellular AIMP1 is quite 
limited.  
Within the MSC, AIMP1 interacts pairwise with arginyl-tRNA synthetase 
(RARS) and glutamyl-tRNA synthetase (QARS) by way of its leucine-zipper N-terminal 
domain36. However, conflicting studies report that AIMP1 neither influences the 
aminoacylation activity of RARS nor alters global protein translation36,37. With its 
ubiquitous and highly conserved nature, therefore, an intracellular function is plausible to 
be independent of its involvement in protein translation, i.e., another moonlighting 
function. A recent report from Sabatini’s laboratory further substantiated the plausibility: 
cells with deletion of QARS and RARS but not AIMP1 did not survive38. 
A previous report from Schwarz’s laboratory showed that part of AIMP1 was at 
the cell surface membrane. The function of surface AIMP1 is not known. Its localization 
suggests that may interact with other components of the cell surface membrane, which 
include, but are not limited to, cytoskeletal proteins such as F-actin, and 
phosphoinositides. Phosphoinositides (PIs) represent only a small fraction of cellular 
membranes but are essential for a very diverse array of signaling pathways. Recent 
studies highlight varying subsets of PIs in physiology, playing a role in cell motility and 
F-actin assembly39,40. 
PIs affect cellular physiology through direct interaction with molecules on either 
side of the lipid membranes found throughout the cell or recruited to the membranes 
(Figure 1.4)41. Many interactions occur through inositide-binding protein modules, such 
as pleckstrin homology or FYVE domains. Recent studies have characterized lipid-
interacting proteins without such inositide-binding protein modules but rather 
intrinsically disordered regions (IDR)42,43. IDRs are proteins sequences that do not 
conform to an ordered three-dimensional structure when expressed yet still functional. 
They generally lack hydrophobic amino acids as interaction with these are not favorable 
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and contain stretches of charged amino acids. However, its role in lung development is 
not known.  
 
 
Figure 1.4. Phosphoinositides have fun. (A) Generalized structure of phosphoinositides, 
including 3 phosphorylated positions and a myo-inositol headgroup. (B) Location of 
phosphoinositides and their respective protein domains to which they interact. 
 
1.4 Overview and Significance of the Thesis 
The remainder of the thesis is divided into four chapters (Figure 1.5). In Chapter 
2, the adapted methodology to quantify gene expression in the developing lung is 
discussed. The methodology found in Chapter 2 is in stark contrast with that found in 
many other studies: purity and integrity utilizing outdated technology, invariable 
amplicons lengths, and data normalization using the overabundant ribosomal subunit 
Rn18s. The adapted approach standardizes the quantification process of the developing 
lung using qPCR while being flexible for adjustments. Standardization of the workflow 
begins with the rapid freezing of the lung tissue that contains high RNase activity and 
then with the verification of the not only purity but also integrity of RNA. Having the 
highest RNA integrity is optimal, but in cases of non-ideal integrity, designing primers 
for short amplicon length and normalizing of the data using multiple, yet biologically 
independent reference genes allowed for flexibility to a certain degree. Data 
normalization using multiple reference genes from independent biological pathways 
minimizes biological and technical error. Application of this approach is to analyze 




Figure 1.5. A schematic presentation depicting the aims addressed in this thesis by 
Chapter (see Section 1.1 Research Outlines and Aims for details). Chapter 2 
addresses a minor aim of developing a tool used to quantify gene expression in lung 
development with an application on assess Vegf mRNA expression. Chapter 3 
addresses the first aim of studying the molecular moonlighting mechanisms of 
elevated EMAP II in the pathogenesis of BPD using a comprehensive, integrated 
approach. Chapter 4 addresses the second aim of characterizing the gene expression 
and signaling mechanisms in macrophages exposed to EMAP II (black and white 
photo of macrophage, adapted from EMBO). Chapter 5 addresses the third aim of 
understanding the moonlighting mechanisms of AIMP1 in lung development. 
Adapted from Schwarz and Cleaver. 
 
In Chapter 3, after establishing the quantitative method, the AIMP1-encoded 
protein is introduced as a therapeutic target in BPD pathogenesis. The study found in 
Chapter 3 address the first aim that is to study the molecular and physiological 
mechanisms of EMAP II during the pathogenesis of BPD. Elevated EMAP II levels in a 
murine model of BPD corroborate the previously identified baboon and human BPD. A 
series of experiments assesses the molecular, structural, and physiological mechanisms of 
EMAP II and its impact on BPD outcomes. In BPD, EMAP II is initially a bronchial 
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club-cell-specific protein-derived factor that later is expressed in galectin-3+ macrophages 
as BPD progresses. EMAP II protein levels is not only increased but also sustained. The 
elevated and sustained EMAP II recruits galectin-3+ macrophages, which is followed by 
an inflammatory state that resembles a severe BPD phenotype characterized by decreased 
pulmonary compliance, arrested alveolar development, and signs of pulmonary 
hypertension as measured by Fulton’s index of right ventricular hypertrophy and elastin 
deposition. Neutralization of EMAP II could reverse the BPD phenotype: inflammation, 
recruitment of myeloid cells, alveolar simplification, and secondary pulmonary 
hypertension. These results are important because of its effectiveness against all BPD 
phenotypes, which appears to be the only study to date that does so while utilizing a 
comprehensive approach to assess molecular, structural, and functional outcomes. 
Neutralization of EMAP II protects against most outcomes of BPD more than other 
previously proposed targets that improve only structure or functional outcomes such as 
pulmonary compliance and usually without regard for secondary pulmonary 
hypertension. 
 In Chapter 4, experiments address the second aim that is to determine the 
molecular mechanisms in the macrophages recruited by EMAP II. The experiments arose 
from the results in Chapter 3 that indicate EMAP II is elevated in macrophages, including 
day 20 when the hyperoxic stimulus had been removed. It is unclear how EMAP II 
affects gene expression in the recruited macrophage and what signaling pathways are 
activated. The experiments utilize thioglycollate-elicited peritoneal macrophages as a 
generalizable model of partially activated, recruited macrophages. The study uses the 
elicited macrophages to measure mRNA of key functional genes in macrophages exposed 
to EMAP II. The transient transcription profile induced by EMAP II does not conform to 
the profiles that are known to be stimulated by the polarizing factors of the macrophage 
polarization spectrum: inflammatory, M1-inducing interferon gamma or the anti-
inflammatory M2-inducing interleukin 4. A luminescence-based screen identified the 
activation of STAT3 by EMAP II. EMAP II activates JAK2 upstream of STAT3. 
Inhibition of the JAK-STAT3 signaling pathway mediates some of the EMAP II-induced 
gene expression profile. 
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In Chapter 5, the study addresses the third and final aim that is to study the role of 
the intracellular AIMP1 in lung development. This is addressed by using a newly 
generated complete knockout mouse (Aimp1 -/-). The progeny of timed heterozygous 
matings are at Mendelian ratios throughout embryogenesis and lung development until 
the day of birth. On the day of birth, the Aimp1 -/- mice exhibit neonatal lethality with 
mild cyanosis yet do not have significantly different wet:dry lung ratios, suggesting a 
lack of pulmonary edema. The morphology of Aimp1 -/- lungs remains normal until the 
saccular stage, when bronchial epithelial cells appear disorganized and Type I cell 
differentiation is significantly decreased. Immunofluorescence analysis confirmed the 
disruption of E-cadherin deposition and focal adhesion dependent F-actin cytoskeletal 
deposition when Aimp1 was ablated compared to its littermate controls.  
In the final chapter, the results of the research and future directions based on the 
results are summarized. The successive outcomes of novel moonlighting mechnisms and 
applications with the aforementioned aims and extensive studies presented in this thesis 
sum up an important contribution to the understanding of lung development and BPD 
etiology in four distinctive, functional significances. First, it reconciles conflicting 
reports of Vegf mRNA expression while delineating a robust workflow to examine gene 
expression in lung development. Second, it identifies new molecular and physiological 
mechanisms of EMAP II in the pathogenesis of BPD using an integrated approach. Third, 
it uncovers new moonlighting functions of intracellular and precursor AIMP1 protein, 
which may aid in effective targeting of EMAP II for BPD. Fourth, it serves as an 




Chapter 2: Adapted approach of mRNA quantification in lung development 
2.1 Introduction 
Gene expression alters mammalian lungs during development, injury, and then 
recovery from either genetic or environmental defect.  The genes encode products such as 
messenger RNA (mRNA), which can be translated into proteins that subsequently 
modulate the above processes.  Understanding changes in gene expression is important in 
order to design new therapies or drugs that can alleviate developmental defects.  Since it 
is not feasible to take lung biopsies from normal human infants, animals such as mice or 
cells are used to examine development and therapeutic strategies.   
There are five stages of normal mammalian lung development: embryonic, 
pseudoglandular, canalicular, saccular, and alveolar.  Gene expression differs not only 
across the stages but also between the cell types of the evolving lung that govern distal 
and alveolar regional development and functionality6. As lung cell type-specific mRNA 
fluctuates during maturation, mRNA transcript number also decreases over time44.  Injury 
during development alters gene expression. Furthermore, disruption in any of the five 
stages generally alters distal lung development results in abnormal formation of air-
exchanging alveoli growth, which usually occurs during the alveolar stage45-49.  The gene 
expressions we quantify in this paper are mRNA levels.  To measure these mRNA level 
changes, we utilize the widely used and highly sensitive quantitative PCR (qPCR) 
technique50. 
Proper assessment and validation of a technique is essential to obtaining robust 
results that minimize variation from developmental changes that occur during lung 
formation and sample processing.  This requires validation of each of the following steps: 
(A) tissue handling including dissection and storage, (B) total RNA extraction, (C) total 
RNA purity and integrity check, and (D) data collection including primer design, and (E) 
data analysis.  
Challenges toward optimal practice are present in lung RNA preparation.  These 
include the time from when a sample is harvested to its storage impacting total RNA 
degradation. Importantly, RNase A, H, and other RNases activity in the lung make it the 
third highest tissue with endogenous RNase activity, only behind the pancreas and spleen.  
During the extraction process, lung tissue remains extremely fragile due to both the high 
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endogenous RNase activity and instable, single-stranded RNA structure, which tends to 
undergo hydrolysis reactions51,52.  Due to these challenges, RNA integrity should be 
determined.  Traditionally, RNA integrity was assessed from the examination of 28S and 
18S bands agarose gel electrophoresis.  This method has been shown to be inconsistent 
and subjective while providing indirect information about messenger RNA integrity53.  
An RNA Integrity Number (RIN) calculated from the Agilent Bioanalyzer 2100 
represents intactness of total RNA including gradient of mRNA degradation and most 
ribosomal sizes including 28S and 18S53,54.  Minimum RINs of either 4.2 or 5 have been 
suggested in non-lung cell types55.  
In addition, variance in qPCR can occur as total RNA in these cells and RNA type 
degradation rates differ.  Therefore qPCR data has to be normalized to minimize the 
variance.  A single, stable gene has not been shown to exist56. Therefore, identifying and 
normalizing by more than a single gene would help yield accurate results56,57.  Frequently 
these listed validation steps in lung development and injury are not widely performed. 
To our knowledge, this is the first lung development and injury paper that utilizes 
these steps and demonstrates consistent expression following evaluation.  Here we apply 
and assess the steps listed above as standard practice of qPCR on a lung developmental 
and injury model.  Genetic deletion models of either one or both alleles encoding 
angiogenic cytokine Vegf-a exhibited vascular defects and are embryonic lethal58.  
Literature using similar variants of an injury model during lung development reports 
conflicting magnitude and direction of Vegf-a expression59-63.  We determined that 
implementation of strict RNA parameters for RNA integrity, purity amplicon length, and 
the identification of stable candidate reference genes enhanced qPCR consistency and 
reproducibility. For normalization of data, reference genes that were independent of each 
other regarded biological function and chance of bias were identified; they were used in 
other lung development and injury studies64,65.  Six candidate genes, Rpl13a, Hprt, Ppia, 
Eef2, Gapdh, and Rn18s were evaluated for their use as reference gene in normalization. 
In contrast to the contradictory Vegf-a expression when normalized to the least suitable 
housekeeping genes, application of this filter and normalization to most suitable three 
housekeeping genes, Hprt, Eef2, and Rpl13a, gave reproducible Vegf-a expression thus 
corroborating the sample filter. Finally, we show that applying these steps listed above in 
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the developing lung, we can circumvent the limitations of qPCR and decreased error 
amplification when comparing the uninjured to injured developing lung.   
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2.2 Materials and Methods 
Developmental Oxygen Injury Mice Model 
C57BL/6 mice were housed in twelve hour light-dark cycles according to the 
Institutional Animal Care and Use Committee approved protocol.  Beginning on postnatal 
day 3, pups were exposed to either 21% oxygen (normoxia) or 85% oxygen (hyperoxia) 
until day 15, n = 6 and n = 6, respectively. Mice dams were kept with their brood until 
postnatal day 4, when they were subsequently exchanged between normoxia and 
hyperoxia every 24 hours to prevent oxygen toxicity. 
 
Lung Organ Harvest 
Pups were humanely euthanized, their lungs excised within three to five minutes 
directly into Eppendorf tubes, snap frozen immediately in liquid nitrogen, and stored at -
80 degrees Celsius for up to one and a half years before analysis.  
 
Primer Design and In-silico Validation 
Primers were designed on IDT or Primer3.  Primers were designed to span introns toward 
3’ end whenever possible, to amplify 65-160 base pair products of gene targets, and have 
little secondary structures.  To check in-silico product specificity and secondary structure, 
primer sequences were entered in NCBI Primer-BLAST for product with no mismatches 
followed by mFold, respectively. 
 
Experimental Primer Validation 
The template to determine primer efficiencies was pooled single-stranded cDNA diluted 
by either ten-fold for reference gene candidates or four-fold for Vegf-a.  All of the 
primers had single melt peak curve and single band when run on 2% agarose gel in TAE 
(data not shown). 
 
RNA isolation 
A coronal section through both the right and left lung was made to include lung tissue 
from the same plane.  The lung cuts weighed about fifteen milligrams and were 
suspended in TRIzol (Invitrogen Cat. No. 15596-026).  The tissue in TRIzol was then 
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homogenized in BBX24 Bullet Blender (Next Advance).  The aqueous portion of tissue 
homogenate was transferred to a Qiagen RNeasy Mini Column (Qiagen Cat. No. 74104).  
Total RNA was isolated from the tissue homogenate according to manufacturer’s 
protocol.  RNA was eluted from the column in 40 microliters of nuclease-free water 
(Ambion Cat. No. AM9937). 
 
RNA Purity then Quality Assessment 
Nanodrop 2000 Spectrophotometer was used to measure UV absorbance ratios of both 
260 nm/280 nm and 260 nm/230 nm, which are expected to be nearly 2 for pure RNA. 
One microliter of eluted RNA was diluted in four microliters of nuclease-free water.  
Two microliters of the diluted RNA was used for spectrophotometer reading. 
 
Quality was assessed by running two microliters of the diluted RNA samples on RNA 
Nano Chip of Agilent Bioanalyzer 2100.  The output of the Bioanalyzer is an RNA 
integrity number (RIN) from scale of 1-10, 1 predicting complete degradation of RNA 
and 10 predicting no degradation.  
 
cDNA synthesis 
500 total ng of each total RNA sample (150 ng/uL) was reverse transcribed by 200 U of 
SuperScript III (Cat. No. 18080-044) reverse transcriptase in 20 microliter reaction 
volume containing 5X First Strand Buffer, 50 ng of random hexamers (Cat. No. 
N808027), 40 U RNaseOUT (Cat. No. 10777-019), 0.1 M DTT, and water. 
 
Quantitative Real-Time Polymerase Chain Reaction (qPCR) 
Reverse transcribed cDNA template was diluted in nuclease-free water to a concentration 
within the 95-106% primer efficiency range determined.  Two microliters of this diluted 
cDNA template was mixed with either 200 nM of each reference gene forward and 
reverse primer or 100 nM of each Vegf-a forward and reverse primer, 2X SYBR Master 
mix (ABI Cat. No. 4472908), and nuclease-free water to make a twenty microliter 
reaction volume.  A no-template control was run along with these reactions.  Reactions 
were run in technical triplicates on ABI StepOnePlus machine at 50°C for 2 minutes, 
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95°C for 2 minutes, and 40 cycles of 95°C for 15 seconds and 60°C for 1 minute.  
Following the run, melting curves were run at ramp rate of 0.2°C per second, obtaining 
single peaks for all products.  Products were run on 2% agarose gel dissolved in TAE 




The algorithm premise is that for two genes to be an ideal reference, the expression ratio 
between them would be the same in all samples.  Beginning from a gene pair, the V value 
is calculated by standard deviation of the ratio of two genes in all samples, followed by 
inclusion of a third gene, and so on.  After including a certain number of genes, the V 
value would increase since the genes with more variance would be incorporated.  The 
number needed for normalization would be the number of genes included before the V 
value significantly increased.  For a final variability value of expression among samples, 
the M value is an arithmetic mean of all V.  Since the lowest V value indicates lowest 
standard deviation of ratio, the genes with lowest M values are less deviating thereby 
more stable than the others67. 
 
Data Processing 
Quantification cycles (Cq) are discrete logarithmic values obtained during exponential 
phase of time continuum when signal is above background threshold.  There is a linear 
relationship between two logarithm scale Cq values.  Residuals with Lowess smoothing 
were plotted to verify linear relationship.  After assessing the relationship, Spearman rank 
correlation coefficient was determined to assess correlation between efficiency-corrected 
Cq values of all candidate reference genes.  For Vegf-a expression analysis, calibrated 
relative quantity values (CNRQ) were calculated, which were normalized to one, two, or 
three reference genes’ relative quantity.  
 
A previous study indicated that mRNA transcripts generally approach normal distribution 
after log-transformation68.  CNRQ values were transformed by factor of log base 2 in 
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order to approximate normal distribution.  Base 2 was chosen to represent the doubling of 
PCR product.   
 
Frequentist Statistical Analysis 
All tests were chosen a priori having noted that the sample population was too small (i.e. 
less than 20) to accurately determine any sample distribution.  In approximate log-normal 
distribution, geometric means of normoxia and hyperoxia Vegf-a CNRQ were calculated 
followed by parametric, unpaired t-test.  Log-transformation generally minimizes 
differences in variance; Lowess smoothing lines of the residuals plotted were fairly flat 
(shown in results, Figure 2.4A).  Together these can satisfy the assumption that there are 
relatively equal variance within each normoxia and hyperoxia distribution.  The satisfied 
assumptions for the unpaired two-sample t-test of Vegf-a levels were that: (a) log 
transformed CNRQ values of both normoxia and hyperoxia sample distributions were 
approximately normal, (b) these sample populations were independent, and (c) log-
transformed variance was relatively equal.  Type I error, α level, was set at 5%, before 
the study.  The null hypothesis for the unpaired t-test that there is no difference of means 
between normoxia and hyperoxia was rejected when p-values were less than the pre-set α 
level; these mean comparisons were then considered statistically significant.  
Bootstrapped 95% confidence intervals were calculated from geometric mean by 
sampling 10000 times with replacement from sample distribution. 
 
qBasePlus Software was used for analysis.  Analysis verification followed by plotting was 
performed using Python 2.7. 
 
2.3 Results 
Characteristics of Selected Genes Studied 
Six genes with known biological functions in lung development and injury 
literature were selected as candidates for the normalization step of qPCR data analysis 
(Table 2.1).  Qualifications as a normalization gene included each gene to have 
independent biological function to reduce the possibility of co-regulation of each other 
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thereby minimizing variation in normalization step.  A literature search did not result in 
any papers suggesting co-regulation among these six genes. 
 
Validating Similar Primer Efficiencies and Specificity  
 After gene selection, primers were designed to target these genes efficiently and 
specifically as possible during qPCR (Table 2.2). To check primer efficiency, known 
quantities of cDNA were serially diluted and plotted against the quantification cycle (Cq) 
that was measured by qPCR (not shown).  Cqs, the qPCR output, are the number of 
cycles needed for the signal measured from theoretical, ideal doubling of transcript 
amplification to cross a set threshold over set time, making Cqs a discrete value.  They 
indirectly represent transcripts per input, and as a result, lower Cqs can be interpreted as 
higher abundance of transcripts. Thus the Cq magnitude is limited by the signal measured 
from transcripts. Primer efficiencies are measured to check not only how specific and 
well primers bind to a template, but also the limits of signal. Efficiencies calculated from 
the slope of these plots were close to 100%, with the range being 95 – 106%, well within 
the generally suggested 90 – 110% range. After qPCR, melting curves of the products 
were run. There was one peak, suggesting specificity (data not shown). In addition to 
melting curves, the products were run on agarose gel and visualized to check for one 
expected-size product (data not shown). Amplicons were predicted by using Primer-Blast 
and UCSC in-silico PCR.  Together these results show specific products. 
 
Highly Pure RNA Did Not Suggest High Integrity of RNA 
Having evaluated primers to be used for qPCR, RNA was extracted from the lung 
tissues. Both 260/280 and 260/230 absorbance ratios of the extracted RNA were assessed 
by Nanodrop 2000 Spectrophotometer (Table 2.3). Only 260/280s ratios are generally 
reported in literature for qPCR since obtaining 260/230 ratios near 2.0 can be dependent 
on tissue type. But for this study, both ratios are greater than or equal to 2.0, indicative of 
pure RNA. Although the RNA was pure, the ratios do not reflect integrity53. Table 2.3 
shows RIN of all samples with the integrity of normoxia RNA samples being 5.0 ± 0.3 
and hyperoxia RNA samples 8.3 ± 0.1 (arithmetic mean ± standard error of mean). 
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Expression Distributions of Candidate Reference Genes  
Following total RNA extraction, total RNA purity and integrity check, we 
performed qPCR to compare mRNA levels in uninjured and injured lungs of newborn 
mice. Including multiple lung samples per group minimized biological variability. Three 
technical replicates per lung RNA sample minimize variability of the Cq reading by 
qPCR. The arithmetic average of the three technical triplicate Cqs of each sample 
represent a single lung sample. A single Cq representing a single sample were then 
plotted to assess the overall distribution (Figure 2.1A). The width of the violin plot 
indicates the number of Cq values at a certain magnitude while the length reflects the Cq 
range. The width increases around 24 Cqs for Rpl13a representing multiple lung samples 
having similar transcript abundance. The Cq magnitude of one gene, Rn18s, is about 10-
15 lower then the other 5 genes. PCR theoretically doubles input, so this indicates that 
Rn18s, a ribosomal RNA, is about 210 - 215 fold more abundant than the other transcripts; 
this holds true because ribosomal RNA, the most stable of all the RNA’s, comprises most 
of the total RNA that was reverse transcribed. 
The RIN of three samples were less than the suggested RIN cutoff of 5, which 
indicated degraded RNA (Table 2.3). When RNA samples with an integrity RIN of less 
than 5 were then excluded, (Figure 2.1B shows the average Cq values following the 
exclusion), the Cq distribution of Eef2, Hprt, Ppia, and Rpl13a all look similar while 
Gapdh does not. There was little change in distribution of Cq values of Rn18s. Not only 
was Rn18s overabundant relative to mRNA, but also was not reflective of RIN, meaning 
any genes normalized to Rn18s would be overestimated. Plots of Cqs grouped by oxygen 
levels show that the lower RIN, degraded RNA samples were in the normoxia group 
(Figure 2.1C, D).  
 
Two Genes Sufficient, But Three Best for Normalization Across Oxygen Injury in 
Newborn Mice 
Acquiring any lung tissue and then RNA extraction from tissue takes precious 
time, money, and effort, requiring cost-effective accuracy in analysis. So the least number 
of genes sufficient for accurate normalization is important, which was determined by 
geNormPlus algorithm’s V value. This V value, further defined in Methods, represents 
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the standard deviation of ratio between a minimum of two genes and three genes. The 
suggested V value cutoff is 0.1557; but this value should be empirically determined. If the 
V value increases as one gene is included in the comparison, then the included gene adds 
deviation. Thus, it is better not to include the gene. V values are plotted in Figure 2.2A 
and 2.2B. Both before and after RIN-based exclusion, the V values of 2/3 and 3/4 
reference genes were relatively similar (shaded bars). Before and after RIN-based 
exclusion, the V value gradually increased as additional genes were included. From this 
analysis, a minimum of two reference genes are needed since inclusion of the third 
candidate gene did not greatly alter V value. The two reference genes were determined by 
the geNormPlus M values, with a low M value correlating with the least deviation while 
the highest value has both the greatest variation and the least reliability. 
 
Eef2, Hprt, and Rpl13a Expression Exhibit the Most Stable M Values After Oxygen 
Exposure 
In contrast to the marked variability of Rn18s and Gapdh M values, Hprt, Eef2, 
and Rpl13a had the lowest three M values among the tested reference genes across 
normoxia and hyperoxia (Figure 2.2C and 2.2D). Even after excluding samples with RIN 
less than 5, Hprt, Eef2, and Rpl13a remained the most stable gene set. Note that before 
and after exclusion, M values of the three genes are close. This suggests that a gene of 
interest normalized to any of the three would be very close, and collectively, all three 
would provide the most accurate normalization. If the two genes are the best reference 
genes for normalization, strong correlation between Cq values can be observed. Cq 
values are on logarithmic scale; when two logarithmic scale values are plotted against 
each other, there usually is a linear relationship. To verify that there was a linear 
relationship between Cq values, residuals of one reference gene mean was plotted against 
another reference gene’s Cq values were plotted along with Lowess smoothing (Figure 
2.3A and 2.3B). Most of the Lowess smoothing of the residuals was generally flat, 
suggesting that there is linear relationship; however, as seen in residual plot of Rn18s 
against Rpl13a, Lowess smoothing was not flat. Since not all relationships were linear, 
correlation between all pairs of reference genes was determined by rank-ordered 
Spearman correlation coefficient (Figure 2.4A and 2.4B). Of all Cq correlation pairs 
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between reference genes in all samples, the largest correlation coefficient was between 
the two most stable reference genes, Rpl13a and Eef2 (ρ = 0.99, p < 0.001). The smallest 
correlation coefficient was between the two lowest ranked reference genes, Rn18s and 
Gapdh (ρ = 0.17). Based on these results, Rpl13a and Eef2 were the two genes used for 
normalization for further qPCR studies. 
 
Vegf-a Expression Decreases in Hyperoxia-Exposed Newborn Lungs When 
Normalized to Eef2, Hprt, Rpl13a  
 Previous studies do not show consensus of Vegf-a expression in the newborn 
model of hyperoxia with these studies relying on a single reference gene for 
normalization (2, 18, 25, 28, 29). For our study, Vegf-a expression was normalized to 
three, two, or one reference genes. Vegf-a expression was normalized to Hprt, Rpl13a, 
and Eef2 in order to calculate relative quantities. The relative quantities of individual 
samples in both normoxia and hyperoxia groups were similar (data not shown).  
Comparing the relative quantities in normoxia against hyperoxia resulted in 3 fold down-
regulation (p < 0.001). In agreement with normalizing to three reference genes, when 
normalized to two genes, Eef2 and Rpl13a, there was still a 2.98 fold down-regulation in 
hyperoxia compared to normoxia (p = 0.001). Even after filtering samples with RIN less 
than 5, Vegf-a expression decreased.    
 
Vegf-a Expression in Opposite Direction When Normalized to Rn18s 
When Vegf-a was normalized to single, lowest ranked Rn18s, there was 2.2 fold 
up-regulation in hyperoxia relative to normoxia (Figure 2.5, p = 0.099). Although this up-
regulation was not statistically significant at our a priori set alpha level, this shows a 
trend that is completely opposite to the direction when normalized to highest ranked 
Hprt, Rpl13a, and Eef2. Importantly, when samples with a RIN of less than 5 were 
excluded and normalized to Rn18s, there was reversal in Vegf-a expression where a 0.07 
fold down-regulation (p = 0.5563) was determined. In contrast to normalizing expression 
by Rn18s, after samples with RIN less than 5 were excluded, Vegf-a expression 
normalized to Hprt, Rpl13a, and Eef2 was still statistically significantly down-regulated 
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by 2.2 fold (p = 0.006). When normalized to Rpl13a and Eef2, there was 2.1 fold down-
regulation (p value = 0.01).  
2.4 Discussion 
qPCR remains widely used as an economical technique to determine and verify 
selected mRNA expression for its high sensitivity69,70. Due to the high sensitivity of this 
technique, we adapted and assessed the steps involved in qPCR to compare transcript 
levels in uninjured and injured developing lungs. Based on high RNase activity, RIN of 
the lung RNA was measured. 
We then sought a way to minimize the impact of inferior RIN. Previous studies 
showed that on one hand, amplicons greater than 400 base pairs were affected by loss of 
RNA integrity and suggested using samples with RIN greater than 5.  On the other hand, 
less than 400 base pair amplicons were minimally affected by RIN71,72. Not only would 
primer efficiency be minimally affected, but also amplicon length would be helpful to 
obtain consistent primer efficiency followed by accurate evaluation of gene 
expression54,72.  Based on the RIN of our samples, primers were designed to generate 
amplicon lengths of 65-160 base pairs long, which is much less than the 400 base pairs 
suggested. This primer validation step is one of many that are known to influence cDNA 
transcription. Other examples include, but are not limited to, the reverse transcription of 
RNA to cDNA and priming strategy73,74. No reverse transcriptase or priming strategy is 
perfect. This study used random hexamers; oligo dT’s are an alternative that could be 
used for isolated poly-A+ mRNA. On one hand, poly-A+ mRNA enrichment followed by 
reverse transcription that includes oligo dT’s can increase signal to noise ratio in qPCR. 
On the other hand, during the enrichment process, there is possible loss of poly-A— tail 
RNA such as deadenylated mRNAs and nuclear mRNAs or 3’ bias of mature mRNAs 
that may of interest. Either case adds additional steps of technical variability. 
This study used these validated primers to determine Vegf-a expression in 
hyperoxia relative to normoxia. Intra-group relative quantities of Vegf-a were similar 
suggesting precision despite three samples with RIN below 5. In addition to comparing 
relative quantities, inter-sample variability was assessed. Bootstrapping the 95% 
confidence interval of Vegf-a expressions implies a lower and upper bound into which the 
mean will fall in 95% of the time. By applying this bootstrap, when normalized to the 
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three reference genes, all normoxia samples overlapped with the confidence interval of 
RIN-based excluded samples (p = 0.999). No statistically significant difference between 
the mean expression of all hyperoxia samples and the RIN-based excluded samples (p = 
0.09) was identified. Similar to expression normalized to the three genes, when normoxia 
samples were normalized to a single gene- Rn18s, there was no difference in Vegf-a 
geometric mean expression (p = 0.999). However, in hyperoxia samples, there was 
statistically significant decrease in the Vegf-a geometric mean expression (p < 0.00001) 
when normalized only to Rn18s. This is in direct contrast to the findings when 
normalized to the three idyllic reference genes. This suggests that normalizing to 
experimentally evaluated, idyllic reference genes reduces the inter-sample variation of 
Vegf-a in the hyperoxia samples even with RIN variation. Furthermore, without adequate 
and reliable genes for normalization, obtaining a robust and accurate interpretation of the 
impact of hyperoxia on Vegf-a expression would be difficult. Not only is there a 
difference in the mean expression in hyperoxia between RIN filtered samples, but also 
Vegf-a expression was contradictory when normalized to a single gene (Rn18s) compared 
to the three stable reference genes. These findings suggest that variable RNA integrity, 
amplicon size, and lack of adequate genes for normalization have given rise to reports 
conflicting in magnitude and direction of Vegf-a expression using similar variants of an 
injury model during lung development.  Based on these results, although a strict RIN 
cutoff of 5 was set, both generating 65-160 base pair amplicons and finding the best 
reference genes to normalize to minimized the effect of RNA integrity on means of Vegf-
a expression. 
Proper normalization was possible by evaluating genes with independent 
biological functions. A dependent function between two candidate reference genes could 
mean co-regulation, producing a multiplicative error if normalized by these genes. 
Applying the geNorm algorithm requires an assumption of genes having independent 
biological function for valid results. 
The six candidate genes were chosen since their biological functions in cells are 
known and used in other fields. Tools such as RefGenes were used to scour public access 
microarray data to propose genes that are similar in expression signal to a gene of 
interest75. However, there was limited knowledge of function for many of the genes, 
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making it difficult to assess independence of biological function. Verifying independence 
of biological function of any candidate reference gene is difficult when RNA amounts 
obtained are small. For example, one of the six candidate reference genes Eef2, 
translational function is predominantly based on phosphorylation. Hyperoxia has been 
speculated to stimulate phosphorylation of Eef2 protein56. However, in Ross et al.’s cell 
culture model, neither mRNA transcript levels were examined nor total Eef2 protein 
levels change56. No other literature suggests hyperoxia affects Eef2. Based on the known 
biological function of Eef2 and our data suggesting that Eef2 transcript levels were not 
affected by hyperoxia, it was used as a reference gene.  
While Eef2 was used as reference, Gapdh and Rn18s were not because they were 
the two least stable genes. This finding corroborates with lung-based literature that 
suggest Gapdh is affected by oxygen level, and this has not shown in any lung 
development models. For example, hyperoxia has been shown to disrupt glycolysis, 
including Gapdh levels, while hypoxia can stimulate HIF-1, which in turn activates 
Gapdh76-78. In contrast to Gapdh, Rn18s levels have not been shown to be regulated by 
oxygen levels. However, Rn18s was still unstable across all samples. Two possible 
reasons that Rn18s was most unstable despite smallest Cq range are (a) overabundant 
Rn18s ribosomal RNA transcript levels would not correlate with mRNA levels in a given 
lung sample since there are different number and types of cells. Within each cell, about 
80% in a total RNA population is ribosomal RNA, of which 18s ribosomal RNA 
comprises about 20%; there is about 1-3% of mRNA in total RNA population. The exact 
same area of lung cannot be sampled, especially in clinical tissue, meaning that there will 
be variable number of cells being sampled. Less confidence can be made about 
normalizing to such an abundant transcript that correlates with neither mRNA levels nor 
RNA integrity. (b) By using same input cDNA amount for qPCR to quantify gene 
expression, Cq values of Rn18s was invariably much lower than the other mRNA genes. 
Describing changes in lower transcript mRNA levels would be less sensitive if Rn18s is 
used for normalization, which is especially true for samples with non-ideal RNA 
integrity. Rn18s represented ribosomal RNA component and would be the last of the 
RNA types to undergo degradation. Furthermore, RNA Polymerase I reverse transcribes 
Rn18s whereas RNA Polymerase II reverse transcribes messenger RNA. The listed 
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reasons above are in contrast to the ideal characteristics of reference genes, which 
include, but are not limited to, most closely reflecting the mRNA transcript stability fo 
the gene of interests, levels, and reverse transcription enzyme; this is to further minimize 
any variance during the qPCR steps. 
Rigorous measures must be employed for validation of RNA integrity. 
Quantification must include multiple reference genes: using a single gene is highly likely 
to yield inaccurate results. Failure to include multiple genes yields conflicting results, as 
we have shown in the case of Vegf-a. In our study, normalizing with both Rn18s and 
Gapdh resulted in means that were outside bootstrapped 95% confidence intervals of 
means generated from normalizing with any of the other stable genes i.e. Hprt, Rpl13a, 
Eef2. These findings further suggest that normalizing with more than one but up to three 
genes i.e. Hprt, Rpl13a, Eef2 result in accurate fold change. 
Our study suggests meaningful PCR results can be obtained despite non-ideal 
RNA in lung development. The criteria for meaningful and reproducible qPCR results in 
lung tissue should include optimization of RNA integrity, both amplicon size and primer 
location, and analysis including idyllic, appropriate rigorously assessed reference genes. 
By following these criteria, this rigor minimized the effect of non-ideal RNA integrity 
typically found in lung-derived RNA.   
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  RIN 260/280 260/230 
Normoxia 3.2 2.0 2.2 
  5.3 2.0 2.4 
  7.4 2.0 2.3 
  3.5 2.0 2.2 
  4.6 2.0 2.3 
  5.9 2.0 2.1 
Mean ± S.E.M. 5.0 ± 0.3 2.0 2.2 
    
Hyperoxia 7.5 2.0 2.0 
  8.8 2.0 2.4 
  9 2.0 2.0 
  8.1 2.0 2.1 
  8.4 2.0 2.3 
  8.2 2.0 2.4 
Mean ± S.E.M. 8.3 ± 0.1 2.0 2.2 
Table 2.3. RINs and absorbance ratios of lung samples. S.E.M: 






Figure 2.1. Quantification cycle (Cq) distribution reflecting differences in mRNA integrity, tissue 
heterogeneity and reverse transcription efficiency, which are reflected in Eef2, Hprt, Ppia, and Rpl13a but 
reflected in neither Rn18s nor Gapdh. The violin plots above show Cq data points of the six candidate 
genes in alphabetical order while representing both the density and spread of Cqs. The width of the plot 
for each gene changes based on Cq density while the height indicates the spread of the Cqs. (A) Cqs of all 
samples show are generally clustered together, except for the two or three apical points representing 
individual samples that are distant from the cluster, which can be reflected by its integrity (n = 12). Due to 
ribosomal transcript overabundance relative to mRNA population, Cqs of Rn18s are much lower while 
showing minimal difference after removing samples with RIN greater than 5. Gapdh has a longer spread 
and less clustering of Cqs compared to Eef2, Hprt, Ppia, and Rpl13a, and can be attributed to reasons 
including the differences in integrity, heterogeneity of lung tissue sampling, or reverse transcription 
efficiencies. (B) Three samples with RIN less than 5 were excluded, Eef2, Hprt, Ppia, Rpl13a all exhibit 
similar distributions whereas Gapdh maintains the largest spread while Rn18s does not appear to change 
at all (n = 9) suggesting that Rn18s does not reflect the change in mRNA. In (C), Cqs are grouped by 
oxygen levels, normoxia and hyperoxia. As mentioned before in (A), the apical points are samples in 






Figure 2.2. Determination of the required number of reference genes for quantitative PCR (qPCR) data 
normalization related to RIN. Two genes are needed for qPCR data normalization, Rpl13a, Eef2, but three 
are best (Hprt) even after excluding samples with RIN less than 5. The required gene numbers are based 
on V value, which is the standard deviation of ratio between expression of two and three reference genes, 
three and four, and so on, in all samples. This increases as less stable genes are incorporated. After 
determining the gene number required for normalization, genes ranked by geNormPlus M Value. A similar 
value indicates less variation among the compared genes. (A) Two or three genes are needed since V 
increases once a fourth gene is incorporated, which are shaded above. There is clearly a fifth gene that 
greatly increases this value with respect to the others. (B) By excluding samples with RIN greater than 5, 
the discrepancy between including and not including a fifth diminishes. (C and D) The two or three genes 
that can be used for normalization are the three highest ranks, namely Rpl13a, Eef2, and Hprt. The two 





Figure 2.3. Lowess smoothing of residuals depicting variance between reference genes. Eef2 and Rpl13a 
demonstrate a strong linear relationship supporting their efficacy as reference genes. Lowess smoothing of 
residuals between two stable genes will be mostly a flat, straight line, which means that there is a strong 
linear relationship. Cqs are logarithmic and the relationship between two logarithmic values can be linear. 
To test this, examples of the residuals are shown. (A) Residuals between the two highest ranked genes 
Eef2 and Rpl13a, vice versa form a nearly flat line. In contrast, (B) there are sharp peaks, exhibiting a non-
linear pattern between lowest-ranked Rn18s and Rpl13a. Since there was still a general trend of liner 
relationship, this suggested preference for a rank-based test, i.e., Spearman correlation test, over a non-




Figure 2.4. Correlation coefficients and M values. Rpl13a and Eef2 demonstrate the highest correlation 
coefficient and the lowest M value and are the most stable reference genes for normalization in qPCR of 
newborn lungs exposed to hyperoxia. A permutation test that samples Cq values from each gene was 
performed to test statistical significance against the null hypothesis that there is zero correlation. Shown 
above are correlation plots of efficiency-corrected Cq between every candidate gene pair. Genes are listed 
in ascending order of the M value rank found in Figure 2.2, C and D. In all samples, the highest Spearman 
correlation coefficient was between Rpl13a and Eef2 (ρ = 0.99, ***P < 0.001) whereas the lowest was 
between Rn18s and Gapdh [ρ = 0.17, not significant (n.s.)]. The highest correlation coefficients suggest 
the stability of the 2 genes for normalization; thereby the 2 genes are most appropriate for normalization. 
A: in Cqs of all samples, correlations between the 2 highest ranked gene pairs are Rpl13a and Eef2. B: the 
highest correlation coefficient was still obtained between Rpl13a and Eef2 after exclusion of samples with 
RIN greater than 5. Because of sample exclusion, the sample size decreased, so the number of possible 
ranks decreased. Hence, Spearman correlation fluctuates. However, permutation test shows highest 
statistical significance between Rpl13a, Hprt, and Ppia. Both lowest coefficients and statistical 



























































































Figure4. Rpl3a and Eef2 demonstrate the highest correlation coefficient, the lowest M value, and are the most stable 
reference genes for normalization in qPCR of newborn lungs exposed to hyperoxia.
A permutation test that samples Cq values from each gene was performed to test statistical significance against the null hypothesis 
that there is zero correlation.  Shown above are correlation plots of efficiency-corrected Cq between every candidate gene pair.  
Genes are listed in ascending order of the M value rank found in Fig. 2C and D.  In all samples, the highest Spearman correlation 
coefficient was between Rpl13a and Eef2 ȡ SZKLOHWKHORZHVWZDVEHWZHHQRn18s and Gapdh 
ȡ QV7KHKLJKHVWFRUUHODWLRQFRHIILFLHQWVVXJJHVWWKHVWDELOLW\RIWKHWZRJHQHVIRUQRUPDOL]DWLRQWKHUHE\WKHWZR
JHQHVDUHPRVWDSSURSULDWHIRUQRUPDOL]DWLRQ$,Q&TVRIDOOVDPSOHVFRUUHODWLRQVEHWZHHQWKHWZRKLJKHVWUDQNHGJHQHSDLUV
are Rpl13a and Eef2%+LJKHVWFRUUHODWLRQFRHIILFLHQWZDVVWLOOREWDLQHGEHWZHHQRpl13a and Eef2 after excluding samples with 
RIN greater than five.  Because of sample exclusion, the sample size decr ased, so the number of possible r nks decreased.  
+HQFH6SHDUPDQFRUUHODWLRQIOXFWXDWHV+RZHYHUSHUPXWDWLRQWHVWVKRZKLJKHVWVWDWLVWLFDOVLJQLILFDQFHEHWZHHQRpl13a, 
Hprt, and Ppia.  Both lowest coefficients and statistical significance was between any pairing using either Gapdh or Rn18s.
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Figure 2.5. Application of the workflow to assess Vegf-a in lung tissue. Vegf-a tissue 
expression is accurately and consistently represented across oxygen levels normalized to 
Hprt, Rpl13a, and Eef2. When normalized to either the 2 or 3 appropriate reference genes 
(Ref.) or Rn18s, there are conflicting Vegf-a mRNA log2-fold changes between lungs 
exposed to hyperoxia and normoxia. Vegf-a expression in all samples appears to increase 
when normalized to Rn18s (P = 0.09, n.s.), but decreases in samples with RIN greater than 5 
(P = 0.56, n.s.). This is in contrast to the expression that statistically significant decreased 
when it was normalized to either the 2 (***P < 0.001) or 3 genes, Hprt, Rpl13a, and Eef2 
(***P ≤ 0.001) both in all samples and after excluding samples (**P < 0.01). 
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Figure 5. Vegf-a tissue expression is accurately and consistently represented in normoxia versus hyperoxia when normalized to 
Hprt, Rpl13a, and Eef2, but inaccurate and inconsistent when normalized to Rn18s. 
When normalized to ithe  the two or three app opriate referen e genes or Rn18s, ther  are conflicting Vegf-a mRNA log2fold changes between 
lungs exposed to hyperoxia and normoxia .  Vegf-a expression in all samples appears to increase when normalized to Rn18s (p = 0.09, n.s.), but 
decreases in samples with RIN greater than 5 (p = 0.56, n.s.).  This is in contrast to the expression that statistically significant decreased when it 
was normalized to either the two (p <0.001, ***) or three genes, Hprt, Rpl13a, and Eef2 SLQERWKDOOVDPSOHVDQGDIWHUH[FOXGLQJ










Chapter 3: EMAP II mediating macrophage migration in BPD pathogenesis 
3.1 Introduction 
Lung disease of prematurity is among the disease states driven by inflammation. 
Placed on supportive care, prematurely born children with underdeveloped lungs 
commonly progress toward development of chronic lung disease, specifically 
bronchopulmonary dysplasia (BPD). Currently, premature birth is the leading cause of 
death in children under the age of five affecting 1 in 10 births and representing 
approximately 15 million births per year worldwide12,16,43,44. In its most severe form, 
BPD can result in secondary cardiovascular sequelae such as pulmonary hypertension 
(PH) that persist into adulthood and abnormal ventilatory response45-50. Despite advances 
in clinical ventilator management, the introduction of surfactant, and antenatal 
glucocorticoids, there is a marked lack of adjunctive therapies. 
Pulmonary inflammation significantly contributes to the multifactorial 
pathogenesis of BPD15,51-54. Like other lung injuries that are driven by inflammation such 
as asthma, in BPD, bronchial epithelial cells and myeloid cells, including, but not limited 
to macrophages are key effectors driving the secretion of both cytokines and chemokines 
such as IL-1β and MCP-1, respectively. 
Clinically, current therapies administered to the premature infants from birth 
include either surfactants to aid alveolar plasticity or glucocorticoids to limit 
inflammation and thereby to prevent BPD progression in premature infants. As expected, 
tracheal aspirates of infants exposed to hyperoxia had elevated inflammatory mediators 
primarily secreted by macrophages, notably IL-1β and TNF-α53,54. In infants with sepsis-
induced inflammation, inhibitors against the two cytokines showed little improvement in 
survival rates; in mouse models treated with inhibitors against these cytokines, only some 
BPD features improved55-59. This suggests that alternative, more broadly functioning or 
upstream targets are needed to prevent BPD.  
In BPD, studies have identified candidate cytokines to be predictive of BPD 
onset. However, the source, function, and physiological mechanisms that drive the 
inflammatory state are poorly understood. In this study, we propose Endothelial 
Monocyte-Activating Polypeptide (EMAP II) as a potential target in the prevention of 
BPD in infants undergoing supportive care with hyperoxia. EMAP II (Aimp1) encodes 
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one component of the Multi-Aminoacyl tRNA Synthetase Complex, is ubiquitously 
expressed, and conserved across species. EMAP II is defined by its secreted, cleaved 
extracellular moonlighting functions with recent studies focusing on its anti-angiogenic 
properties21,24,28,33,60. EMAP II has also been indirectly shown to recruit macrophages in 
various injury models30,61,62. EMAP II expression localizes between the epithelial/ 
mesenchymal interface in early stages of normal murine lung development, while later 
saccular and alveolar developmental stages coincide with low levels of EMAP II 
expression confined to the perivasculature27,29. 
We previously identified an association between elevated EMAP II levels and 
BPD in premature baboon and human infants34. As a result, we hypothesized that EMAP 
II drives macrophage recruitment in BPD, which intensifies the inflammatory state. 
Using three mouse models, we identified sources of EMAP II throughout BPD 
progression and showed functional roles for EMAP II in the disease progression of severe 
BPD. We determined not only that its chemotactic role on macrophages leads to an 
inflammatory state exacerbating the development of BPD, but also represents a specific 




C57BL/6 mice were obtained from Jackson Laboratories. Studies complied with the 
animal protocols approved by the Indiana University Institutional Animal Care and Use 
Committee. Newborn pups were randomly selected for treatment groups while mice dams 
were exchanged every 24 hours to prevent oxygen toxicity. For details on normoxia and 
hyperoxia treatments, see Figure 3.1A. Regarding recombinant EMAP II injection 
studies, see Figure 3.2A. Antibodies neutralizing EMAP II were delivered according to 
Figure 3.4B. 
 
Mouse model of bronchopulmonary dysplasia and therapy 
Newborn pups were randomly selected to receive either rabbit non-specific 
immunoglobulin G or rabbit anti-EMAP II neutralizing antibody (2 mg/kg) as illustrated 
in Figure 3.4C above. Bronchopulmonary dysplasia during alveologenesis was then 
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modeled and illustrated in the above figure63. To collect tracheal aspirates from mice, a 
small incision was made along with the anterior portion of the trachea. An angiocatheter 
was then inserted within the tracheal incision. Two hundred microliters of fluid was 
inserted and aspirated. Fluid was then centrifuged at 5,000 g for 5 minutes at 4°C. 
 
EMAP II treatment of mice 
Mice were subcutaneously injected with recombinant EMAP II (80 μg/kg in 100 μL) 
daily beginning from day 3 to day 14 as shown in Figure 3.2. This dosage had been 
previously established as having an anti-angiogenic effect64. 
 
Immunoblotting 
Sections of the right lung were placed in tubes containing modified lysis buffer. The 
tubes were then placed and homogenized in Bullet Blender Storm (BBY24M, Next 
Advance Inc.). Protein concentrations were determined by Bradford reagent (Bio-Rad). 
Twenty micrograms of lung tissue homogenates were loaded into NuPage Novex 4-12% 
Bis-Tris Protein gels (Invitrogen), incubated in 20% ethanol for 5 minutes, and 
transferred onto nitrocellulose membranes using iBlot v2 (Invitrogen). The membranes 
were placed in 5% blocking buffer (BioRad) in Tris-buffered saline with 0.05% Tween-
20 for 1 hour at room temperature. Membranes were incubated overnight at 4 oC in 
primary antibodies listed in Supplementary Table. 
 
Lung Microscopy 
Lung tissues were inflation fixed by dripping 4% paraformaldehyde (w/v in PBS) at a 
height of 25 cm mm·H2O above the lung for 10-15 minutes. Lungs were excised from the 
mouse en bloc and placed in 4% paraformaldehyde overnight before embedding in 
paraffin. Embedded tissues were sectioned 5.0 μm thick (Zeiss). Antigen retrieval and 
antibody staining was performed according to Table 3.1. Hematoxylin and eosin staining 
and Masson’s Trichrome staining was performed according to manufacturer’s 
instructions (Thermo Fisher). Co-localization staining was performed using Enzymatic 
double-staining IHC kit (Abcam). Images were captured on Hammamatsu Orca-ER or 
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DP70 camera at magnifications indicated in the appropriate figure legends using CellSens 
software.  
 
Lung Morphometry Analysis 
Mean linear intercepts and radial alveolar counts were calculated from H&E stained lung 
sections counted blind, decoded65. 
 
Pulmonary Function Testing 
Only male mice were tested for pulmonary functions to minimize possible confounders 
related to estrogen. Mice were anesthetized with ketamine (100 mg/kg) and xylazine (6 
mg/kg) followed by pancuronium (1 mg/kg) to induce paralysis. A metal cannulus was 
inserted through a small incision in the trachea followed by single-model and complex 
model measurements of lung function using FlexiVent Software (SCIREQ Inc.).  
 
Macrophage Count 
Light microscopy images were taken on Olympus using MicroBiological Suites with a 
40X objective lens. The images were then randomized and the number of Galectin-3+ 
positive cells were counted in a blinded manner. The images were then decoded and 
analyzed using Python. 
 
Quantitative PCR 
Lung harvest, RNA extraction, RNA quality determination, quantitative PCR, and 
analysis were performed according to the methods in a previous study66. Primers are 
listed in Table 3.1. 
 
Transmigration Assay 
RAW264.7 cells were cultured in phenol-red free DMEM media containing 10% FBS, 
antimicrobial and antifungal supplement, 5 mM HEPES, and 5 mM L-Glutamine until 
approximately 70 – 80% confluency. The media was then exchanged for transmigration 
media which contained phenol-red free DMEM containing 1% FBS for 2 hours before 
being scraped, incubated in CD16/32 to block non-specific F’ab interactions on ice for 
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approximately 15 minutes; the media containing the antibody was centrifuged at 400 x g 
for 5 minutes at 4 oC and aspirated. 5 x 104 cells were resuspended in transmigration 
media and loaded into a single 5.0-micron pore transwell insert. Regarding treatments in 
Figure 4, EMAP II protein was either boiled for 30 minutes at 100°C or pre-incubated 
with EMAP II neutralizing antibody at room temperature for 30 minutes at respective 
dosages. LPS (Serotype E. Coli 055:B4, Sigma) was also pre-incubated with EMAP II 
neutralizing antibody. The bottom inserts were filled with 500 microliters containing the 
listed treatments. Transmigration occurred for 4 hours at 37oC, fixed in 4% 
paraformaldehyde (w/v in PBS) overnight, and stained in crystal violet solution. Images 
were captured at 20X magnification on DP70 using MicroSuite Biological Software. n = 
4-6 for each treatment.  
 
Outliers 




EMAP II levels in lung disease of prematurity. We exposed neonatal mice to 85% O2 
saturation level (i.e. hyperoxia) compared to room air (normoxia) during lung 
alveologenesis to induce BPD formation (Figure 3.1A). EMAP II protein levels were 
quantified by immunoblotting (Figure 3.1B). Confirming previous studies, EMAP II 
expression was perivascular in normoxic day 5 (Figure 3.7). Compared to mice at 
normoxia, EMAP II levels were significantly elevated in lungs of mice exposed to 
hyperoxia over time, peaking at postnatal day 15 (Figure 3.1C) (from hereon, mice 
exposed to hyperoxia and analyzed between 5 to 15 days are termed “early BPD mice,” 
mice analyzed at later time points are termed-15 days, “BPD mice,” and for 20 days and 
beyond, “late BPD”). However, analysis of EMAP II protein levels in tracheal aspirates 
of BPD mice revealed an early increase at day 10 but a decline toward that of normoxia 
control mice by day 15 (Figure 3.1F).  
 
EMAP II expression differs in location during BPD formation. 
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A significant increase over time in whole lung but decreasing trend in tracheal 
aspirates suggested that EMAP II expression is localized and compartmentalized in 
response to hyperoxia. EMAP II has been shown to augment inflammatory cell counts67. 
We proposed that the localization of EMAP II would be distributed in cells near the 
tracheal aspirate collection site and thus histological analysis by co-staining EMAP II 
with Galectin-3 (known as GAL-3), an activation and differentiation marker of 
macrophages was performed. In contrast to normal perivascular localization of EMAP II 
expression, by day 5, EMAP II expression was found in both proximal bronchiolar 
epithelial-rich regions, indicated by club-cell-specific-protein expression, and 
perivasculature (Figure 3.1D). By day 10, EMAP II expression was limited to GAL-3+ 
macrophages that were located in both bronchiole and distal airways (Figure 3.1E); 
subsequently by day 15, EMAP II was localized only within macrophages of the distal 
airways. In agreement with the localization moving distally away from bronchiolar 
airways, analysis of tracheal aspirates showed a significant decrease in EMAP II 
expression (Figure 3.1F).  
 
In vivo effect of EMAP II on macrophages. As there was a recruitment of macrophages 
over time found in BPD mice (Figure 3.1E), we postulated that excess EMAP II in early 
BPD directly recruited macrophages. We administered recombinant EMAP II to mice 
until the time point when there was maximal EMAP II expression on day 15 (Figure 
3.2A). The dosage followed previous studies that determined the alternate moonlighting 
anti-angiogenic role of EMAP II64; as previously observed, there were decreased 
angiogenic genes without a compensatory effect on transcription (Figure 3.8A,B). We 
found a significant increase in the number of macrophages in lungs of mice administered 
EMAP II as compared to controls (Figure 3.2B,C). This suggested that there was direct 
macrophage chemoattraction by EMAP II.  
 
The pro-inflammatory cytokine interleukin-1 beta (IL-1β) has been a target of interest in 
the pathogenesis of BPD. As it is primarily secreted by macrophages, and having seen a 
significant increase in macrophage recruitment, we evaluated IL-1β expression in whole 
lung (Figure 3.2D). There was significantly elevated IL-1β expression in lungs 
 47 
 
administered EMAP II (Figure 3.2D,E) suggesting contribution to macrophage 
pulmonary sequestration. 
 
Effect of EMAP II on lung structure and BPD pulmonary outcomes. In addition to 
increased macrophage counts in mice administered EMAP II, we observed loss of lung 
structural integrity similar to that of BPD. As EMAP II has other reported functions, we 
sought out to define effects of sustained, elevated EMAP II on the lungs. Compared to 
control mice, the body weight of mice administered EMAP II was significantly lower, 
suggesting impaired overall growth (Figure 3.8B). Lungs of EMAP II-administered mice 
had severely dysplastic alveoli and increased elastin deposition (Figure 3.3A,F). There 
were larger distal airspaces as evidenced quantitatively by both significantly decreased 
radial alveolar count (RAC) and increased mean linear intercept (MLI) (Figure 3.3B,C). 
This suggested that excess amounts of EMAP II impaired development of the lung 
structure. However, structure does not always correlate with lung function or outcome 
measurements68. Compared to control, mice given EMAP II had significantly impaired 
pulmonary biophysical properties: the pressure volume loop was shifted downward, 
suggesting an inability of lungs to maximally inflate along with other biophysical 
properties (Figure 3.3D, Figure 3.8C). To test whether impaired lung biophysical 
properties were due to surfactant expression, we measured surfactant protein-C (SP-C), a 
common indicator of type II alveolar epithelial cells that secrete surfactants. Compared to 
controls, mice administered EMAP II had significantly elevated mRNA and protein 
levels of SP-C (Figure 3.7D,E). This suggested a compensatory mechanism in response 
to exogenous EMAP II thus the lung function change was independent of a lack of SP-C. 
 
EMAP II-treated mice presented with signs of pulmonary hypertension. Macrophage 
counts were elevated following EMAP II injection, and previous studies link both the 
elevated counts and subsequent inflammatory cytokine release to pathogenesis of not 
only BPD but also its secondary sequel, pulmonary hypertension (PH)69,70. Lungs of mice 
injected with EMAP II had impaired alveolarization and blood vessel formation leading 
to decreased function, reflecting anti-angiogenic properties of EMAP II (Figure 3.3A); 
clinically, this implies cardiovascular sequelae, which are also prominent in poor 
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outcome of BPD patients47,50. We observed right ventricular hypertrophy in mice given 
EMAP II compared to controls (Figure 3.3E). Consistent with right-heart hypertrophy 
found in PH, we observed increased elastin deposition by Masson’s Trichrome staining in 
distal vessels (Figure 3.3F).  
We concluded that chronic, elevated EMAP II led to BPD-like disease, including 
the development of signs of secondary PH. As SP-C levels were not decreased by EMAP 
II yet elevated EMAP II levels and macrophage recruitment were found in BPD, an 
alternative mechanism of upregulating EMAP II in early BPD must exist that modulates 
macrophage recruitment, negatively influencing lung and heart outcomes. 
 
Neutralizing excess EMAP II limits chemotactic effects upon macrophages. We 
tested if we could limit macrophage recruitment by neutralization of excess EMAP II. 
Using an EMAP II-neutralizing antibody (referred to as anti-EMAP II), we assessed 
macrophage transmigration in vitro. Consistent with the in vivo findings, we found that 
exogenous EMAP II significantly increased macrophage transmigration (Figure 3.4A,B). 
However, anti-EMAP II incubated with excess EMAP II significantly neutralized this 
chemoattraction in a dose-dependent manner (Figure 3.4A,B). As a control, heat-
inactivating EMAP II did not increase the number of transmigrated cells. Macrophage 
chemotaxis was specific to EMAP II and further confirmed by treating cells with LPS, an 
inflammatory agent with a role in macrophage migration and activation, and anti-EMAP 
II (Figure 3.2A,B).  
 
To assess whether we could prevent hyperoxia-induced BPD formation, mice were 
randomized and given the neutralizing anti-EMAP II antibody (Figure 3.4C). Delivery of 
antibody to lungs was confirmed (Figure 3.9A). Recruitment of macrophages in BPD 
mice was assessed by immunohistochemistry (Figure 3.4D). Following treatment with 
anti-EMAP II, however, there was a significant decrease in the number of macrophages 
and inhibition of a BPD-like phenotype (Figure 3.4E).  
 
Neutralizing excess EMAP II improved lung structure and development of altered 
function. We considered that the inhibition of macrophages through neutralizing excess 
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EMAP II in BPD would mitigate murine pulmonary damage. The body weight of 
hyperoxia mice treated with anti-EMAP II was comparable to control groups kept in 
room air (Figure 3.9B). Following treatment (Figure 3.4C), there was an increase in the 
number of distal alveoli measured in blinded manner, and a visible lack of bronchiolar 
vessel distension (Figure 3.5A). As associated with parameters of the qualitative findings, 
there was a significant decrease in MLI counts, which reflects a decrease in empty air 
space (Figure 3.5B). RAC counts in lungs of mice treated with anti-EMAP II appeared to 
increase compared to control non-specific IgG (Figure 3.5C). By limiting macrophage 
recruitment, the hyperoxia mice treated with anti-EMAP II showed an improvement in 
pulmonary outcomes compared to mice treated with control IgG (Figure 3.5D, Figure 
3.9E). There was a possibility that this improvement was not due to limiting macrophage 
recruitment but perhaps prevention of cellular apoptosis induced by either hyperoxia or 
EMAP II. We found increased apoptosis due to hyperoxia but an insignificant decrease 
following anti-EMAP II treatment (Figure 3.9C). Another alternative mechanism would 
be an increase in surfactant production. SP-C did not significantly change following anti-
EMAP II treatment, suggesting that the treatment was independent of surfactant 
production (Figure 3.9D). 
 
Anti-EMAP II treatment reduced signs of PH. To test whether anti-EMAP II treatment 
could impact development of PH, we assessed right ventricular hypertrophy. 
Significantly decreased right ventricular (RV) weight was seen in hearts of hyperoxia 
mice treated with anti-EMAP II over that of mice treated with control IgG, comparable to 
that of mice in room air (Figure 3.5E). Consistent with right ventricular hypertrophy, we 
observed that there was elastin deposition in distal alveolar vessels (Figure 3.5F). 
 
Reducing macrophage numbers resolved inflammatory and chemotactic gene 
expression. We proposed that by limiting macrophage recruitment through anti-EMAP 
II, we would reduce the levels of pro-inflammatory and chemotactic gene expression. By 
immunoblotting, we detected IL-1β levels in lungs of hyperoxia mice (Figure 3.6A). 
Elevated IL-1β levels were significantly reduced in the hyperoxia mice treated with anti-
EMAP II (Figure 3.6B). In addition, expression of pro-inflammatory genes, Tnfa, Il6, 
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Il1b and chemotactic genes, Ccl2, Ccl9 were markedly decreased following anti-EMAP 
II treatment (Figure 3.6C).  
 
3.4 Discussion 
Premature birth, a major determinant of neonatal morbidity and mortality, is 
associated with long-term health consequences at an estimated expense of $26 billion per 
year in the United States alone. Lung disease of prematurity, BPD, is a preterm 
complication without a specific targeted treatment. After a call for more directed studies 
on pulmonary inflammation in BPD, clinical studies determined that inflammatory 
markers are not only elevated in BPD but associated with prognosis15,54,71. Some studies 
used untargeted anti-inflammatory therapies such as glucocorticoids, direct cytokines, or 
chemokines with minimal improvement in some attributes of BPD58. 
In contrast, our results provide an opportunity to consider targeting pulmonary 
immune response by addressing macrophage infiltration as a therapeutic component of 
BPD. Our experiments show that EMAP II is a specific target that directly contributes to 
the pathogenesis of premature lung disease in BPD. This is manifested when elevated 
EMAP II was sustained in lungs of BPD mice compared to controls, corroborating the 
temporospatial-dependent role of EMAP II in BPD development of baboons and humans 
– specifically, in the bronchial epithelium rather than in perivasculature, where it is 
normally expressed and declines over time34. In addition to sustained levels, the direct 
effect of EMAP II on BPD development was evident when mice treated with EMAP II 
developed a BPD-like phenotype: arrested alveolar development, right ventricular 
hypertrophy consistent with PH, macrophage recruitment, and heightened inflammatory 
state. Subsequently, anti-EMAP II treated mice in hyperoxia presented with a significant 
reduction in the inflammatory state and of the BPD-like phenotype. 
The bronchial epithelium has recently been identified as the initial source of an 
immune response in various injury contexts72,73. Similarly, early marked elevated EMAP 
II expression in primary bronchial CCSP+ cells following hyperoxia support the role of 
EMAP II as an inflammatory modulator in BPD development. Improvement in both 
macrophage counts and inflammation following anti-EMAP II treatment ascribes to its 
chemotactic function compared to its known anti-angiogenic function24,25,27,28,33,34,60. 
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Neutralization of EMAP II limited chemotaxis of macrophages in cell culture and into the 
lung, ultimately limiting inflammation. Given the proximal CCSP+ cell expression of 
EMAP II followed by macrophages expressing EMAP II in BPD mice, there exists a 
possible positive reinforcing cycle. Epithelial cells such as the CCSP+ cells express 
EMAP II, which recruits macrophages; these cells, in turn, can produce more EMAP II, 
which further propagates and activates other immune cells. If this is the case, a novel 
mechanism can be substantiated in clinical BPD development as a potential therapeutic 
target through the continuous presence of EMAP II. 
Moving away from a simple dichotomy in macrophage activation reveals the 
many varying functional subsets in not only other disease contexts but also BPD. Two 
recent studies indicate that rather than a simple dichotomy in macrophage activation, a 
threshold of varying functional subsets of unknown origins (e.g. blood-derived 
circulating, bone marrow egression) is at least sufficient for BPD progression58,74. The 
first showed that elevated macrophage numbers in conjunction with pro-inflammatory 
gene expression resulted in BPD despite decreased counts of immune response cells58. 
This suggests that a hyperactivated macrophage subset is crucial in hyperoxia-induced 
inflammation. The second study defined an alternative macrophage-like CD11b+ 
monocyte origin that protected BPD mice independent of neutrophilia74. However, 
macrophage pro-inflammatory response is not only limited to lung disease of prematurity.  
In agreement with the cited studies, our study implicates that the increased 
number of effectors cells due to EMAP II can significantly influence physiological 
function. Before any meaningful function is assigned to subsets recruited by EMAP II, 
further studies are awaited that determine the origin and functional consequence in 
normal lung development including that of the CD11b mononuclear subset. 
A previous study showed that elevated macrophage numbers in conjunction with 
pro-inflammatory gene expression resulted in BPD despite decreased counts of immune 
response cells58. This suggests that hyperactivated macrophages may play a significant 
role in hyperoxia-induced inflammation. However, macrophage pro-inflammatory 
response is not only limited to lung disease of prematurity. Using this study of BPD as a 
working model the complex interactions of macrophages and their environment can be 
equally implicated as contributing or driving factors in other chronic inflammatory 
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disease such as Crohn’s disease or rheumatoid arthritis75-77. Inhibition of excess 
macrophage numbers supports normal lung development, informing potential anti-
inflammatory therapies.  
In BPD, hyperoxia-induced inflammation has also been linked to impaired lung 
biophysical properties, but with conflicting results, as both increasing and decreasing 
compliance has been described78,79. Some studies suggest that hyperoxia increased 
compliance resembling emphysematous lungs, while other studies concluded hyperoxia 
decreased compliance due to the lungs being less pliable78-80. We tested murine 
pulmonary outcomes at 6 weeks in concordance with previous studies68,78,80. Sustained 
EMAP II was associated with decreased compliance (Figure 3.3D). For this reason, other 
biophysical properties, such as resistance, also need to be taken into account. Since 
impaired biophysical properties are collective, insufficient oxygen exchange, 
inflammation, and subsequent right ventricular hypertrophy contribute to pulmonary 
dysfunction. However, following anti-EMAP II treatment, vessels were not thickened, an 
indication of PH. Suppression of EMAP II inflammatory properties alleviated these 
pulmonary biophysical abnormalities associated with hyperoxia induced BPD including 
decreased resistance, decreased tissue damping, and decreased airway space.  
Our results highlight an EMAP II-mediated inflammatory mechanism as a 
significant component of the multi-factorial pathogenesis of lung disease of prematurity, 
BPD. In contrast to other studies, the results of our experiments show not only robust 
protection from a BPD phenotype and signs of secondary PH but also reduction of 
macrophage recruitment and inflammatory status. Neutralization of EMAP II and curbing 
its ability to chemoattract macrophages is a possible future therapeutic goal in the 






3.5 Figures and Tables 
 
 
Figure 3.1. Expression of Endothelial monocyte-activating polypeptide II (EMAP II) in murine model of 
bronchopulmonary dysplasia (BPD). (A) Experimental schematic of neonatal mouse oxygen exposure to 
induce BPD. (B) EMAP II protein expression and (C) quantification in whole-lung lysates of normoxia 
and hyperoxia mice (normalized to β-actin, pooled samples of at least n = 3 for Day 3, n = 2 for Day 30, 
n = 3–4 for Day 10, n = 6–10 for other days; at least two independent experiments). Main effect of oxygen, 
**P = 0.0000322, interaction of oxygen:age, P = 0.788. (D) Representative images of 
immunohistochemical co-staining for EMAP II expression (red) and Clara cell secretory protein (green). 
Purple indicates co-expression. Scale bar, 20 μm. (E) Representative images of immunohistochemical 
staining for EMAP II expression (red) and galectin-3 (green). Purple indicates co-expression. Scale bar, 
100 μm. Note that compared with lungs exposed to normoxia, those exposed to hyperoxia and harvested 
on Day 15 were severely dysplastic so that both the bronchial epithelium and the alveoli could not be 
imaged in the same capture field, although the same magnification as that used in other images was used. 
(F) EMAP II concentration in tracheal aspirates by immunoblotting and quantification. Main effect of day, 
P = 0.0187; interaction of oxygen:day, P = 0.711; n = 3 per day. Data are presented as mean ± SEM. 






Figure 3.2. EMAP II protein mediates macrophage chemoattraction in vivo. (A–E) Mice treated with either 
EMAP II or vehicle (injection) from Days 3 to 15. (A) Schematic of EMAP II treatment in neonatal mice. 
(B) Representative immunohistochemical images of distal alveoli in lung sections of Day 15 mice showing 
macrophage (galectin-3, red) and (C) quantification by blinded analysis of galectin-3–positive cells per 
HPF (n = 4, ****P = 0.00000235). (D and E) Immunoblot probed for IL1β in whole lung lysate of Day 15 
mice (normalized to β-actin, **P = 0.01, n = 4). Scale bar, 100 μm. Results are representative of four (B 
and C) or two (D and E) independent experiments. Data are presented as mean ± SEM. HPF, high-powered 







Figure 3.3. Lungs treated with EMAP II present BPD–like phenotype. The experimental 
design is the same as in Figure 3.2A. (A) Comparison of distal alveolar structure in inflation-
fixed lungs (25 mm Hg) of mice killed on Day 15 by (B) mean linear intercept (****P = 
0.00000719), and (C) RAC by blinded observer analysis (n = 8, *P = 0.03337). (D) 
Biophysical parameters of lung function compliance, resistance, and elastance were assessed 
(n = 3–6; *P = 0.011, **P = 0.023, *P = 0.008, respectively) and representative pulmonary 
flow loops presented. (E) Right ventricular hypertrophy quantified by Fulton’s index (n = 6 
mice per group, **P = 0.00520) and (F) representative deposition of perivascular elastin 
(arrows) in distal lung tissue sections stained with Masson’s trichrome. Scale bars, (A) 100 
μm and (F) 10 μm. Results are representative of three (A–C and F) or two (D and E) 
independent experiments. Diamonds are data points past 75%. Data are presented as 





Figure 3.4. Neutralizing EMAP II limits macrophage recruitment both in vitro and in vivo. (A) 
Quantification of Transwell-migrated macrophages in response to EMAP II vehicle (phosphate-
buffered saline), nonspecific IgG, and EMAP II preincubated with various concentrations of anti-
EMAP II (n = 2–4 replicates, P = 0.0044, one-way analysis of variance across treatments). (B) 
Schematic of neonatal hyperoxia exposure protocol used to induce BPD, inj. of anti-EMAP II or IgG. 
(C) Representative immunohistochemical images of distal alveoli in lung sections showing 
macrophages (galectin-3, red) and (D) galectin-3–positive cells per HPF, quantified by blinded 
analysis (n = 4 mice, ***P = 0.000457). Results are representative of samples collected from four (D 







Figure 3.5. The rescued lung structure and function of BPD mice that are treated with anti-EMAP II. 
The experimental design is the same as in Figure 3.4B. (A) Comparison of distal alveolar structure in 
inflation-fixed lungs (25 mm Hg) of mice killed on Day 15 by (B) mean linear intercept and (C) 
radial alveolar count by blinded observer analysis (n = 8; ****P = 0.0337, P = 0.08898). (D) 
Biophysical parameters of lung function compliance, resistance, and elastance were assessed among 
hyperoxia groups (n = 6–8 mice; ***P = 0.00642, ***P = 0.000209, ***P = 0.00183) and 
representative pulmonary flow loops presented. (E) RV hypertrophy quantified by Fulton index (ratio 
of RV weight to LV plus septal weight, n = 3, **P = 0.00537) and (F) representative deposition of 
perivascular elastin (arrows) in distal lung tissue sections stained by Masson’s trichrome. Scale bars, 
(A) 100 μm and (F) 10 μm. Results are representative of four (A–F) or two (D–F) independent 







Figure 3.6. Neutralizing EMAP II limited macrophage recruitment and caused 
inflammation induced by high oxygen to subside. (A and B) Representative 
immunoblot probed for IL1β in whole lung lysate of Day 15 mice and quantified 
(n = 3, normalized to β-actin, *P = 0.0498). (C) mRNA expression of inflammatory 
Il1b, Il6, and Tnf and chemokine genes Ccl2 and Ccl9 in lungs determined by 
quantitative polymerase chain reaction calculated on the basis of Hprt, Eef2, and 
Rpl13a expression (n = 6–7; *P = 0.0195 [II1b], **P = 0.0489 [Tnfa], **P = 0.00594 
[II6], **P = 0.00227 [Ccl2], P = 0.0889 [CcI9]). Samples are from three independent 







Figure 3.7. Perivascular EMAP II expression. Representative images of IHC co-
staining for endomucin (green) and EMAP II (red) in Lungs of neonatal day 5 mice 







Figure 3.8. EMAP II protein induced compensatory mechanisms. The experimental design is the 
same as Figure 3.2A. (A) mRNA expression of Kdr and Flt1 in lung tissue was determined by qPCR, 
calculated on the basis of Eef2, and Rpl13a expression (n = 4, p = 0.130, 0.582). Values are 
expressed as arithmetic mean ± 1 s.e.m. (B) Comparison of body weight on day 15 of life (n = 6, p = 
0.0258). (C) Biophysical parameters of lung tissue damping and tissue elastance were assessed (n = 
3-6 mice, p = 0.00466, 0.00928). (D, E) Immunoblot of SFTPC protein expression and mRNA 
expression of Sftpc determined by qPCR calculated on the basis of Hprt, and Rpl13a expression (n = 







Figure 3.9. Neutralizing EMAP II compensatory mechanisms in BPD mice. The 
experimental design is the same as Figure 4C. (A) Representative images of antibody 
deposition (arrows) in day 15 lungs. Scale bars, 20 μm. (B) Comparison of body weight on 
day 15 of life (n = 17 per group, p = 0.00789). (C) Quantification of immunofluorescent 
TUNEL assessment of apoptosis in day 15 lungs by blinded observer analysis (n = 8, 3 
fields per mouse, main effect of oxygen, p = 0.0000236, main effect of antibody, p = 
0.728, interaction of antibody:oxygen, p = 0.732). (D) Quantification of Surfactant protein 
C expression by Western blotting densitometry (n = 6 per group, p = 0.732, two-way 
ANOVA). (E) Biophysical parameters of lung tissue dampening and tissue elastance were 








Target Assay ID Vendor 
Il1b qMmuCID0005641 BioRad 
Tnf qMmuCED0004141 BioRad 
Il6 qMmuCID0005613 BioRad 
Ccl2 qMmuCEP0056726 BioRad 




Antigen Clone Company  Catalog No. Usage Antigen Retrieval Dilution 
IL1B 3A6 Cell Signaling 12242S IB -- 1:1,000 
ACTB 8H10D10 Cell Signaling 3700S IB -- 1:10,000 
SPC -- EMD 
Millipore 
AB3786 IB, IHC None 1:1,000 
GAL-3 M3-38 Antibodies-
Online 
ABIN1804652 IHC Citrate 1:1,000 
CCSP -- Seven Hills WRAB-3950 IHC Citrate 1:1,000 
CD16/32 93 eBioscience 130-0161-82 Transwell   








Table 3.1. The primers and antibodies used in the performed experiments of Chapter 3. 
Target Sense Antisense Length 
Hprt CCCCAAAATGGTTAAGGTTGC AACAAAGTCTGGCCTGTATCC 76 
Eef2 ACATTCTCACCGACATCACC GAACATCAAACCGCACACC 135 
Rpl13a TCCCTCCACCCTATGACAAG GTCACTGCCTGGTACTTCC 136 
Kdr GTACCGGGACGTCGACATAG TCACTGACAGAGGCGATGAA 79 
Flt1 ACTCTTGTCCTCAACTGCAC GGTCAATCCGCTGCCTTATAG 112 
Sftpc ATGGACATGAGTAGCAAAGAGGT CACGATGAGAAGGCGTTTGAG  
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Chapter 4: The transient activation of JAK-STAT3 in macrophages by EMAP II 
4.1 Introduction 
Macrophages serve as key effector cells of innate immunity in tissue homeostasis, 
injury, and repair. During tissue injury and repair, critical functions include, but are not 
limited to, promoting recruitment of other inflammatory cells, phagocytizing of injured 
tissue, and mediating both the tissue remodeling process and more recently, the re-
vascularization process79,80. Accordingly, macrophages remain adaptable to its 
environment by altering its highly plastic transcriptional profile, a process referred to as 
macrophage polarization. 
Secreted factors in a milieu of injuries are the effectors that ultimately modulate 
macrophage transcriptional profiles. Previous studies highlight chemokine-like, yet 
pleiotropic ligands, secreted in the milieu of injuries that recruit monocytes and 
lymphocytes while impacting vasculature in injury processes. Endothelial monocyte 
activating polypeptide II (EMAP II) is an ancient and conserved among many species with 
pleiotropic effects: act upon endothelial cells of the vasculature through integrin-mediated 
mechanisms while recruiting hematopoietic derived cells81. 
Historically, EMAP II was identified in supernatant of fibrosarcoma-derived cells, 
a protein of approximately 23 kilodaltons (kDa), and discovered to induce tissue factor 
secretion, release of von Willebrand Factor, and expression of adhesion molecules in 
endothelial cells while promoting secretion of TNF-α32. Subsequent studies implicated 
transient, high amounts of EMAP II can disrupt vessel formation through inhibition of 
vascular endothelial growth factor-2 signaling and its downstream transcriptional 
effects23,82. 
We recently discovered a role for EMAP II in innate immunity as a recruiter of 
myeloid cells and as a ‘find-me’ signal, one that goes beyond vasculature. ‘Find-me’ 
signals such as EMAP II recruit phagocytes not only to maintain tissue homeostasis but 
also in injured states; if left unchecked, excessive amounts can actually promote further 
apoptosis and cellular damage. In line with this concept, we showed in a prior study of a 
murine model of bronchopulmonary dysplasia, not only was there a persistent expression 
of EMAP II in the macrophages that were recruited even after the injury stimulus, i.e., 
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high oxygen levels, was removed, but also an increased number of macrophages in 
response to EMAP II83.  
However, the molecular mechanisms that occur in the recruited cells are unknown. 
Disrupted VEGFR2 signaling is a common signaling mechanism for the effects of EMAP 
II upon vasculature, however, only subsets of macrophages, primarily tumor macrophages, 
can express VEGFR2. This makes disrupted VEGFR2 signaling highly unlikely to 
contribute toward signaling in the recruited macrophages84,85. 
In this report, we set out to identify transcriptional effects and signaling events of 
EMAP II within the recruited macrophages. We characterized both the kinetics of 
transcriptional expression and determined the signaling mechanisms that were mediated 
by EMAP II in partially activated thioglycollate-elicited macrophages (TEPM). We 
hypothesized that recruited macrophages would shift toward an inflammatory polarized 
state by gene expression and signaling upon exposure EMAP II, but the results showed 
otherwise; rather, we found gene expression and signaling uncharacteristic of either 
macrophage polarization states. Our findings not only underscore the plasticity of 
macrophage transcription, but also extend mechanistic insight beyond of the vasculature 
and into the dynamics of EMAP II on recruited macrophages. 
 
4.2 Methods 
All studies complied with the animal protocols approved by the University of Notre 
Dame/Indiana University Institutional Animal Care and Use Committee. 
 
Cell culture and primary macrophage preparation. Four percent (w/v) thioglycollate 
broth dissolved in sterile water was injected intraperitoneally into gender-matched, 6-12 
weeks old C57BL/6 mice (Jackson Laboratories). Seventy-two hours following injection, 
peritoneal macrophages were collected by flushing the peritoneal cavity with 8 mL of PBS 
containing 5% (v/v) EDTA. Any red blood cells, if any, were lysed with red blood cell 
lysis buffer (Biolegend) for 5 minutes at room temperature. The cell suspension was then 
centrifuged, counted, and re-suspended to a concentration of 2 x 106 cells/mL in DMEM 




EMAP II Preparation 6x-His tagged EMAP II was prepared as mentioned previously33. 
The endotoxin levels in all preparations used for this study were below detectable limits, 
containing <0.1 ng/EU (GenScript). Also complementarily to this, as seen in the results, 
there was a minimal difference in NF-κB activation between EMAP II and its control, 
which is consistent with a previous report88. 
 
RNA Isolation and qPCR—Total RNA and qPCR was performed as previously 
described except with the following66: RNA isolation was performed with Direct-zol 
(R2050, Zymo Research). 
 
TEPM Treatments, Cell Fractionation, Immunoblotting, and Cytokine Analysis. 
Cells were plated at 2 x 106 cells per well in 12-well plate containing 1 mL of media, were 
rested at 37oC with 5% (v/v) CO2 for 2-4 hours, washed at least 2 times with PBS, and 
then replaced with DMEM containing 1% (v/v) FBS overnight. The following morning, 
cells were treated with EMAP II (2 μg/mL) for the indicated time points. At the end time 
point, cell lysis followed by immunoblotting was performed as previously described85. 
Antibodies against total Histone H3, JAK2 (Y1007), STAT3 (Y705), and ACTB were all 
obtained from Cell Signaling Technology. Cellular fractionation to obtain cytoplasmic and 
nuclear isolates of TEPMs was performed using the Pierce NE-PER kit per manufacturer’s 
instructions. At the end point, the supernatant was collected, centrifuged at 12,000 g at 
4oC for 5 minutes to clear debris, frozen in liquid nitrogen, and stored at -80oC until 
further analysis by Eve Technologies (Canada). 
 
Luminescence assay. Following the previously mentioned macrophage preparation and 
suspension, 10 x 106 TEPMs were seeded in a 10 cm petri dish. After overnight incubation 
with DMEM containing 1% (v/v) FBS, TEPMs were exposed to either vehicle or EMAP 
II (2 μg/mL). Once nuclei were isolated, the transcription factor activation assay was 
performed using 5 micrograms of nuclear isolate and as per manufacturer’s protocol 
(Signosis). Once luminescence signals were obtained, fold changes were calculated and 




Luciferase assays. HEK293-T cells were cultured in DMEM media containing 10% 
serum (Seradigm). 1 x 105 cells were reverse transfected with 200 ng of pGL3-STAT3 
and 10 ng of pRL-null vectors (Promega Inc.) using Attractene (Qiagen) as per 
manufacturer’s protocol. Cells were then incubated with either EMAP II, IL-6 
(BioLegend) or both. Following overnight incubation with the listed ligands, the cells 
were lysed with Passive Lysis Buffer (Promega) and luciferase assay performed as per 
manufacturer (Dual-Glo Luciferase Assay, Promega). HEK293-T cells (ATCC) were 
tested for mycoplasma. 
 
4.3 Results 
Time-dependent, distinct transcriptional profile induced by EMAP II in partially 
activated thioglycollate-elicited macrophages (TEPM). Similar to other secreted 
cytokines, there is most likely a dynamic, transient transcriptional profile. Messenger 
RNA expression of genes notable in macrophage function was measured over a time 
course by quantitative PCR analysis (Figure 4.1). Expression levels of most genes in 
partially activated macrophages typically peaked between approximately 2 and 4 hours but 
all subsided by 21 hours. This indicates a transient response of macrophages exposed to 
EMAP II. It was expected that the expression levels of both inflammatory and chemokine 
effector genes would increase24,85,89. Accordingly, Tnf, Il1b, and Il6 peaked nearly 
concurrently by 2 hours and subsiding by 4 hours while Nos2 peaked later by 4 hours and 
subsided by 21 hours. Likewise, with EMAP II as an effector of myeloid cell recruitment, 
chemokinic genes were also expected to increase. The transient profiles of Ccl2 and Ccl9 
were similar to that of the inflammatory effector genes – peaking by 2 hours and subsiding 
by 4 hours; meanwhile, Ccl5 increased and remained elevated at the end of the time 
course by 21 hours (Figure 4.1A).  
A part of the plastic transcriptional response of macrophages, levels of anti-
inflammatory genes typically increase as a means of a brake to the inflammatory process. 
Il10, a key anti-inflammatory gene, significantly increases when exposed to pathogens or 
typically between 2 and 4 hours17,90. However, upon EMAP II exposure, Il10 was actually 
decreased by 1 through 4 hours before returning nearly to baseline (Figure 4.1B). 
Although Il10 did decrease, anti-inflammatory markers Mrc1 and Retnla did not over the 
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time course (Figure 4.1C). Interestingly, a key gene in macrophage metabolism of 
arginine, Arg1 levels increased by 0.25 hours (i.e. 15 minutes) and remained elevated until 
3 hours; an inhibitor of JAK-STAT signaling, Socs3 peaked at 2 hours (Figure 4.1C). 
Collectively, this transient transcriptional response in macrophages exposed to EMAP II is 
unlike that of other reported highly macrophage-polarizing secreted factors, suggestive of 
a unique, EMAP II-specific, distinct transcriptional profile. 
 
Profiling for activated transcription factors in macrophages exposed to EMAP II. We 
noted the unique transcriptional profile in macrophages exposed to EMAP II. The 
transcription factors that are activated in response to EMAP II are unknown. According to 
classical transcription factor signaling principles, the activation of transcription factors 
typically includes phosphorylation followed by a translocation from cytoplasm to nucleus 
where it binds to DNA. We performed a luminescence-based screen that compared 
phosphorylated, translocated transcription factors contained in nuclear isolates 
fractionated from TEPMs treated with EMAP II for 2 hours to untreated nuclear isolates 
from TEPMs to experimentally identify EMAP II-activated transcription factors. STAT3 
was the most highly activated transcription factor (Figure 4.2). Notable was a lack of 
difference in NF-κB p65 luminescence signal (Figure 4.2), an inflammatory transcription 
factor; similarly, there were minimal differences in both nuclear translocation and 
phospho-serine phosphorylation of the inflammatory transcriptional mediator, NF-κB p65 
(Figure 4.3D).  
 
EMAP II-induced tyrosine phosphorylation of STAT3 is time dependent. We focused 
on STAT3, as it was the highest ranked transcription factor associated with gene 
transcription programs that are anti-inflammatory. Interestingly, STAT3 activation was in 
direct contrast to our hypothesis of activation of a pro-inflammatory transcription factor91. 
Activation of STAT3 by Y705 is typically temporally dynamic. Time course dynamics 
revealed a biphasic pattern with peak activation of Y705 phosphorylation of STAT3 by 
approximately 0.25 and 4 hours (Figure 4.3A). These results show that there was a very 




Increased promoter STAT3 activity following exposure to EMAP II. The level of 
transcriptional expression of any gene can vary despite promoter activity. We measured 
the functional activity of STAT3 based on its binding to a consensus-binding element, c-
fos sis-inducible element region by luciferase assay. Cells transfected with STAT3 
transcriptional reporter plasmids were exposed overnight to either EMAP II or a positive 
well-established acute STAT3 activator, interleukin (IL-6). EMAP II alone increased 
transcriptional activity, although less than IL-6 (Figure 4.3B). These results show that 
EMAP II does modestly increase STAT3 transcriptional activity. 
 
EMAP II induced STAT3 phosphorylation by JAK. There are many kinases that 
phosphorylate STAT proteins, including, but not limited to, Src, JAK1-3, or Protein 
Kinase C. A brief 2-hour pretreatment with JAK-STAT inhibitor, ruxolitnib, decreased 
nuclear translocation of STAT3 (Y705) comparable to control (Figure 4.3E). There was 
rapid JAK2 activation in macrophages exposed to EMAP II (Figure 4.3C). While EMAP 
II activated STAT3, pre-treatment of TEPMs with ruxolitinib, a specific inhibitor of 
JAK1/2, ablated EMAP II-mediated STAT3 (Y705) (Figure 4.3D). Complete ablation of 
phosphorylation made it unlikely that another kinase such as Src was involved in the 
activation of STAT3. As an additional control, we confirmed that STAT3 activation is 
EMAP II specific by pre-treating TEPMs with either functional neutralizing antibody of 
EMAP II or non-specific IgG; compared to control, pre-treatment with the neutralizing 
antibody of EMAP II did prevent STAT3 activation (Figure 4.3D). Together, these results 
suggested that EMAP II-mediated STAT3 phosphorylation occurred primarily through 
JAK. 
 
EMAP II increased Y705 STAT3 into the nucleus. To validate the screen and increased 
STAT3 promoter activity downstream of JAK, we fractionated nuclei from macrophages 
that were pretreated with either ruxolitinib or its vehicle, DMSO, followed by the addition 
of EMAP II. Supporting previous results of the activation of JAK-STAT signaling, a 1.6-
fold increase in phosphorylated STAT3 (Y705) translocation to the nucleus verified the 
screen, as well as a 2.0-fold increase in the cytoplasmic fraction (Figure 4.3E). These 
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results indicate phosphorylated STAT3 translocates to the nucleus in TEPMs exposed to 
EMAP II, downstream of JAK-STAT. 
 
STAT3 transcriptional activity is distinct to EMAP II and not dependent on either 
autocrine IL-6 or IL-10. Both IL-6 and interleukin 10 (IL-10) are well-established 
activators of STAT3 (Y705). Based on transient mRNA expression changes in both Il6 
and Il10 in TEPMs exposed to EMAP II, it is possible that the translated and secreted 
cytokines would cause an autocrine, indirect STAT3 activation. To rule out this 
possibility, we measured secreted IL-6 and IL-10 in supernatants of TEPMs exposed to 
EMAP II overnight. There was an insignificant difference in levels of both IL-6 and IL-10 
(Figure 4.4A), suggesting that an indirect STAT3 activation by EMAP II through 
autocrinic activation due to these cytokines was highly unlikely. Levels of transcripts Il6 
and Il10 were measured in TEPMs pretreated with either ruxolitinib or its vehicle 
followed by exposure EMAP II. Similar to the time course, Il6 levels were significantly 
increased but were not rescued by ruxolitinib pretreatment (Figure 4.4B), suggesting that 
neither Il6 nor Il10 are regulated through JAK-STAT signaling.  
 
EMAP II increases both JAK-STAT independent and dependent gene expression 
and cytokine secretion. We noted that there was a discrepancy between the mRNA 
increases and cytokine secretion while ruling out JAK-STAT3 activation by autocrine 
feedback. To measure acute transcriptional effects of JAK-STAT signaling, we pre-treated 
TEPMs with ruxolitinib or vehicle for 2 hours before the addition of EMAP II and then 
measured expression levels of Il1a, Socs3, and Csf3, which are downstream targets of 
JAK-STAT3 signaling. Whereas all three genes significantly increased after exposure to 
EMAP II, only Il1a was not significantly reduced by pre-treatment with Ruxolitnib 
(Figure 4.5A). To assess how JAK-STAT3 affects cytokine secretion, we exposed TEPMs 
to EMAP II with or without pre-treatment of Ruxolitinib and measured varying secreted 
cytokine levels in media. Both IP-10 and CCL2 (MCP-1) expression, important 
chemokines, did increase; however, its secretion was not reversed by JAK-inhibition 
suggesting other regulatory mechanisms are involved (Figure 4.5B). Consistent with other 
reports of other anti-angiogenic factors, exposure to EMAP II induced significant VEGF 
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secretion that was JAK-independent. Consistent with a JAK-STAT signature, both IL-1α 
and G-CSF secretion by EMAP II was elevated and could be prevented by JAK inhibition, 
suggesting a JAK-dependent cytokine secretion (Figure 4.5C). 
 
4.4 Discussion 
The results yield at least three new insights into the function of EMAP II on 
recruited matured macrophages: (1) it produces rapid changes in the transcriptional profile 
of macrophages that is not consistent with known pro- or anti-inflammatory programs; (2) 
it activates STAT3; (3) through JAK2. Local tissue mediator EMAP II recruits myeloid 
cells to sites of injury. However, molecular mechanisms of macrophages upon recruitment 
and its activation upon exposure to EMAP II is not well known in part due to its poorly 
understood leaderless-sequence-driven secretion, making difficult to genetically target it. 
Therefore, with an ex-vivo model, this study explores the response of matured, partially 
activated, and recruited macrophages to EMAP II. 
Macrophages dynamically respond to their environment through polarization. In 
TEPMs exposed to EMAP II, the changes in inflammatory gene expression found in 
Figure 4.1 were suggestive of an activation of inflammation but unique comparatively to 
other known inflammatory mediators of macrophages. The unique response to EMAP II in 
macrophages is in line with what recent reports suggest in similar ex vivo systems – that 
the transcriptional profile is both not as dichotomous as once viewed in the past and is 
unique to an individual ligand17. For active pro-inflammatory shift, there is generally a 
consistent suppression of its counterpart, anti-inflammatory genes that was absent in our 
study. As examined by qPCR in Figure 4.1, although there was an early suppression of 
Il10, there was a lack of noticeable suppression of other anti-inflammatory genes Mrc1, 
Retnla; further, the Il10 expression returned to baseline unlike other inflammatory 
mediators92. Notably, the rapid induction of Arg1 seen as early as 15 minutes of exposure 
to EMAP II in this murine system is unlike other ligands that typically require at least 24 
hours for maximal induction. The results here show that there is a unique, transient EMAP 
II-mediated, transcriptional reprogramming that can occur in recruited macrophages. 
In searching for transcription factors activated by EMAP II, STAT3 was indeed 
activated as evidenced by the luminescence screen, functionally shown by measuring 
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promoter activity and key STAT3 target gene expression, downstream of its kinase 
JAK1/2. This is consistent with that of other ‘find-me’ signals such as sphingosine-1-
phosphate and macrophage migration inhibitory factor that can also activate JAK-
STAT393. Whereas JAK-STAT target gene Socs3 is an inhibitor of endothelial cell 
angiogenesis, its function in macrophages remain unclear as to as to whether it is 
important for the initiation or resolution of inflammation. There were clearly transient 
increases in its gene expression, partially mediated by the acute pre-treatment of JAK-
STAT inhibitor. The transient increase suggested that there not only might be an EMAP 
II-mediated STAT3 role in macrophages but also other transcriptional complexes. Other 
activated STAT transcription factors can complex with STAT3 such as STAT1, but upon 
further examination, there were minimal, detectable changes in tyrosine phosphorylation. 
Many of the measured target genes can also be differentially regulated by NF-κB (p65), a 
transcription factor of many inflammatory genes especially in macrophages. There was a 
minimal difference in NF-κB activation, a transcription factor important for the activation 
of many of these genes88.  
Consistent with other “find-me signals” such as CX3CL1 or sphingosine-1-
phosphate, the EMAP II-induced increase in tyrosine phosphorylation of STAT3 validated 
the transcription factor activation screen. Upon validation, there was a biphasic response 
STAT3 tyrosine phosphorylation similar to the response to IL-6, suggesting autocrinic 
mechanisms. In contrast to IL-6, EMAP II induces a longer window of STAT3 
phosphorylation between each phase. Additionally, there may be an autocrinic mechanism 
to prolong the phosphorylation by known factors such as IL-6, IL-10, or EGF. However, 
in response to EMAP II, there was not a significant difference in both IL-6 and IL-10 in 
supernatants. Increased transcriptional activity suggest an autocrine feedback mechanism 
in favor of an IL-6 independent STAT3 activation by EMAP II. Future studies will 
identify the factors for the latter, prolonged STAT3 activation. 
This is the first report of STAT3 activation in macrophages following exposure 
with EMAP II that has been regarded generally as a pro-inflammatory cytokine. Based on 
our previous study and results presented here, there may be different regulatory 
mechanisms of JAK-STAT3 activation that result in distinctive target genes. A reasonable 
expectation would be, similar to other pro-inflammatory ligands that signal through 
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JAK/STAT3, that only certain pools of STAT3 complexes are activated. Thus, the target 
genes of STAT3, such as IL-1A, G-CSF (encoded by Csf3), SOCS3 or MCP-1, that are 
activated by EMAP II should be reversed by inhibition86,87. Indeed, in our study, the 
elevation of STAT3 target cytokines such as IL-1A or G-CSF was prevented by JAK-
STAT inhibition, but neither STAT3 target gene MCP-1 nor VEGF were inhibited. A 
possible explanation to be explored is that the transcription factor, nuclear factor 1 (NF-1) 
as seen in our screen, can also directly regulate MCP-1 expression94. Future studies will 
further explore the transcription factor complexes downstream of EMAP II-induced JAK-
STAT signaling, including, but not limited to, NF-1 and those that may cooperate with 
STAT3. 
The activation of STAT3 raises many possibilities into further mechanisms of 
EMAP II. For example, there may be early-phase and late-phase-specific STAT3 complex 
formations induced by EMAP II similar to TNF or other “find-me” signals. Initially, there 
might be an overall activation of inflammatory genes defined by competition of activated 
transcription factors on gene promoters; later, the complexes could rearrange to yield an 
anti-inflammatory profile. Our data presented in this dissertation highlight particularly 
early transcriptional changes in macrophages in response to EMAP II. Interestingly, some 
of these changes were reversed with the inhibition of JAK-STAT signaling suggesting that 
this competition might be controlled by upstream events. We show that the STAT3 
activation was JAK1/2 dependent, similar to what is known about IL-6-dependent JAK-
STAT activation. As seen in other modules of signaling by cytokines such as IL-6, 
typically the ligand binding to its receptor causes conformational change to activate the 
JAK family then recruit and phosphorylate STATs. Therefore, it is plausible that although 
not yet identified, EMAP II has multiple receptors, of which some of them function 
through JAK. Another laboratory suggested CXCR3 to be a receptor of EMAP II on 
endothelial cells but this has neither been shown in macrophages95 nor has CXCR3 been 
shown to interact with JAK. Without receptor identification of EMAP II, it remains 
unclear if there are other factor(s) responsible for prolonging the observed biphasic JAK-
STAT3 activation. For example, factors such as IL-6 or IL-10 can often prolong or 
promote STAT3 re-activation through autocrinic mechanisms. However, in our 
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experiments, we did not see a significant release of either factor, suggesting that neither 
factor is responsible for the observed STAT3 reactivation at 24 hours. 
This study identifies a JAK-STAT molecular signaling pathway partially mediated 
by EMAP II in the recruited macrophage population following injury. We propose that 
after serving a role as a “find-me” signal in injury, EMAP II elicits a subset of STAT3 
genes in recruited, activated macrophages. Its expression generally localized near the site 
of injury, suggesting it to be a local mediator of gene expression. This is supported by 
mixed and transient STAT3 signaling partially mediated through JAK in macrophages to 
activate them to a unique inflammatory profile. Overall, this presents an opportunity for 
future studies to explore the re-programming of macrophage gene expression induced by 







Figure 4.1. EMAP II activates a distinct, transient transcriptional profile in macrophages. Thioglycollate-
elicited peritoneal macrophages were treated with EMAP II (2 µg/mL) for a time course of 21 hours as 
indicated. Quantitative PCR of (A) inflammatory, (B) anti-inflammatory Il10, and other genes associated 
with (C) an anti-inflammatory state in macrophages. Indicated on the line graphs is the arithmetic mean ± 
one standard error of mean (n = 3 independent TEPM isolations). 
 
  
Figure 1. EMAP II activates a unique, transient transcriptional profile in macrophages. Thioglycollate-elicited
peritoneal macrophages were treated with EMAP II (2 µg/mL) for a time course of 21 hours as indi ated.
Quantitative PCR of (A) inflammatory, (B) anti-inflammatory Il10, and other genes associated with (C) an 
anti-inflammatory state in macrophages. Indicated on the line graphs is the arithmetic mean ± one standard
error of mean (n = 3 independent isolations). Indicated on the line graphs is the arithmetic mean ± one
standard error of mean (n = 3 independent TEPM isolations). For all genes in A-C, except Mrc1 and Retnla, 







Figure 4.2. EMAP II mediated changes in transcription factor activation. Nuclei 
were isolated from TEPMs exposed to either vehicle (PBS) or EMAP II (2 μg/mL). 
Listed are the activated and de-activated nuclear transcription factors (TF), including 
STATs and NFkB, ranked by log2 transformed fold change (Log2FC) between 
EMAP II and vehicle treatments. 
 
  
Figure 2. EMAP II mediated changes in transcription factor activation. Nuclei were isolated from TEPMs 
exposed to either vehicle (PBS) or EMAP II (2 μg/mL). Listed are the activated and de-activated nuclear 
transcription factors (TF), including STATs and NFkB, ranked by log2 transformed fold change (Log2 FC)




















Figure 4.3. EMAP II-mediated activates JAK-STAT3 signaling. (A) STAT3 activation is time-dependent. 
TEPMs treated with EMAP II (2 μg/mL) for the indicated times and immunoblotted for Y705 STAT3. 
Results are representative of 3 independent, gender-matched experiments. (B) EMAP II induces STAT3 
transcriptional activity. HEK293-T cells were reverse transfected with 200 ng of pGL3-STAT3 and 10 ng 
of pRL-null vectors then exposed overnight to vehicle, EMAP II, IL-6 (20 ng/mL) or a combination of 
both. Results are representative of 4 similar experiments each with at least 2 well replicates. (C) EMAP II 
induces STAT3 phosphorylation that is mediated by JAK2. TEPMs were treated with EMAP II and 
immunoblotted for phosphorylated JAK2, indicating activation. (D) TEPMs were pre-treated with control, 
non-specific rabbit IgG antibody (5 μg/mL) or EMAP II neutralizing antibody (5 μg/mL) for 1 hour and 
then treated with EMAP II (2 μg/mL) for 15 minutes. JAK1/2 dependency was assessed by pre-treating 
TEPMs with vehicle (DMSO) or Ruxolitinib (1 μM) followed by the addition of EMAP II for 15 minutes. 
Lysates were then immunoblotted for tyrosine phosphorylation of STAT3. Results are representative of 
(C) 3, (D) 2 independent experiments.(E) Nuclear translocation of phosphorylated STAT3. RAW264.7 
cells were treated with vehicle or Ruxolitinib for 2 hours before the addition of EMAP II (2 µg/mL) for 15 
minutes. Cells were then fractionated into nuclear and cytoplasmic fractions. Histone H3 was used to 





Figure 4.4. STAT3 activation does not depend on secreted IL-6 and IL-10. (A) Secreted 
IL-6 and IL-10 were measured in supernatants from TEPM exposed overnight to EMAP II 
(2 μg/mL) or control. Indicated is representative of one experiment containing three 
individual TEPM preparations. The experiment was performed twice with similar results. 
Indicated on the line graphs is the arithmetic mean ± one standard error of mean (n = 3 
independent TEPM isolations). PBS was used as vehicle and a control. (B) Il6 and Il10 
transcript levels measured in TEPM with the same experimental conditions as (A). 
Indicated are the arithmetic mean ± one standard error of mean (n = 3-4 independent 




Figure 4. STAT3 activation does not depend on secreted IL-6 and IL-10. (A) Secreted IL-6 and IL-10 were
meDsXred iQ sXperQDtDQts Irom 7EPM exposed overQight to EMAP II (2 μg/m/) or coQtrol IQdicDted is 
represeQtDtive oI oQ  experimeQt coQtDiQiQg three iQdividXDl 7EPM pr pDrDtioQs 7he experimeQt ZDs
perIormed tZice Zith similDr resXlts IQdicDted oQ the liQe grDphs is the Drithmetic meDQ  oQe stDQdDrd
error oI meDQ (Q    iQdepeQdeQt 7EPM isolDtioQs) PBS ZDs Xsed Ds vehicle DQd D coQtrol (B) Il6 and 
Il10 trDQscript levels meDsXred iQ 7EPM Zith the sDme experimeQtDl coQditioQs Ds (A) IQdicDted Dre the 
Drithmetic meDQ  oQe stDQdDrd error oI meDQ (Q    iQdepeQdeQt 7EPM isolDtioQs)  p-value   








































Figure 4.5. Cytokine profile induced by EMAP II in TEPMs. TEPMs were treated with 
EMAP II (2 µg/mL) overnight, and secreted cytokines quantified. (A) JAK-independent, 
EMAP II-mediated cytokines. Inhibition of elevated, secreted JAK-STAT3 target 
cytokines (B) JAK-dependent cytokine secretion. (Following one-way ANOVA, Tukey’s 
HSD: PBS vs. EMAP II **p-value ≤ 0.01, EMAP II vs. Ruxolitinib + EMAP II, *p-value 
≤ 0.05). Indicated is the arithmetic mean ± one standard error of mean (n = 3 independent 
TEPM preparations). Represented is one of 2 experiments. (C and D) Transcript levels 
following JAK-STAT inhibition. TEPMs were either pretreated with Ruxolitinib or 
vehicle (DMSO in PBS) for 2 hours, then EMAP II (2 µg/mL) was added for 2.5 hours. ** 
p-value ≤ 0.001 compared to vehicle; ++ p-value ≤ 0.001 compared to EMAP II. Indicated 





Figure 5. Cytokine profile induced by EMAP II in TEPMs. TEPMs were treated with EMAP II (2 µg/mL) overnight,
and secreted cytokines quantified. (A) JAK-independent, EMAP II-mediated cytokines. Inhibition of elevated, 
secreted JAK-STAT3 target cytokines (B) JAK-dependent cytokine secretion. (Following one-way ANOVA,
 7XNe\·s +S' PBS vs EMAP II pvDlXe   EMAP II vs 5XxolitiQiE  EMAP II pvDlXe  ) IQdicDted
 is the Drithmetic meDQ  oQe stDQdDrd error oI meDQ (Q    iQdepeQdeQt 7EPM prepDrDtioQs) 5epreseQted is 
oQe oI 2 experimeQts (& DQd ') 7rDQscript levels IolloZiQg -A.S7A7 iQhiEitioQ 7EPMs Zere either pretreDted
 Zith 5XxolitiQiE or vehicle ('MS2 iQ PBS) Ior 2 hoXrs theQ EMAP II (2 g/m/) ZDs Ddded Ior 2 hoXrs
  pvDlXe   compDred to vehicle  pvDlXe   compDred to EMAP II IQdicDted is the Drithmetic 
















































Figure 4.6. Transcripts induced by EMAP II in RAW264.7 cells. (A) Transcript levels of the same 
target genes as shown in Figure 4.5. Genes were measured in RAW264.7 cells transfected with 
either scrambled or siRNA against Stat3 then exposed to EMAP II (2 µg/mL). (B) Immunoblot of 
total STAT3 amounts and loading control b-actin. Indicated is the arithmetic mean ± one standard 
error of mean (n = 3 replicates, 2 independent experiments.) 
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Chapter 5: The critical role of AIMP1 in lung development  
5.1 Introduction 
During mammalian lung development, precise coordination of signaling events 
occur. The five stages of the development, in mice, begin with the embryonic phase 
(~E9.5-E10.5) and transitions to the “pseudoglandular” phase (~E10.5-E16.5) when 
epithelial buds emerge and branch into its surrounding mesenchymal interface to produce 
the respiratory bronchial tree8. Following these two stages, during the “canalicular” 
(~16.5-E17.5) and “saccular” (~E17.5 until postnatal day 0.5) phases, the surrounding 
mesenchyme becomes less predominant while distal epithelial tubules remodel to form 
primary septae – they subdivide eventually into primitive alveolar sacs.  
Beginning partially in the canalicular stage, alveolarization begins when epithelial 
progenitor cell populations within the outwardly growing tubules differentiate into Type I 
or II alveolar epithelial cells or pneumocytes in order to mediate gas-exchange and 
surfactant synthesis, respectively. The epithelial-mesenchymal interface is the site of 
continual exchange of signaling factors that spatiotemporally guide proper sacculation3. 
Numerous studies describe factors necessary for early lung budding and respiratory 
branching. However, the mechanisms of those factors that control the formation of 
interface are not well known. 
Factors important for sacculogenesis are expressed at the epithelial-mesechymal 
interface, but so far, only a few have been identified3,88. The 34 kilodalton Aminoacyl 
tRNA Synthetase Interacting Multifunctional Protein 1 (AIMP1) is expressed at the 
interface of epithelial and mesenchymal cells throughout murine development. Its 
expression in the lung inversely correlates with the vascularization that begins in the 
canalicular stages. Structurally, AIMP1 has 3 domains: (1) an N-terminal leucine zipper, 
coiled coil; (2) intrinsically disordered region; (3) C-terminal Endothelial Monocyte 
Activating Polypeptide II (EMAP II). The N-terminal domain interacts with components 
of tRNA synthetases while the intrinsically disordered region (IDR) lacks a specific 
three-dimensional structure89. As a result, they were presumed to lack any physiological 
function including that found in AIMP1. However, recent studies have identified liquid-
like properties of IDRs that allow them to transiently interact with molecules on either 
side of lipid membranes such as phosphoinositides, which are very crucial signaling 
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components of cellular motility and epithelial cellular polarity, or other intracellular 
components such F-actin41,90,91. Consistent with other proteins that contain IDRs, AIMP1 
localizes to the cell surface membrane92,93. However, its function has not yet been 
characterized. Although functions of EMAP II have been characterized in various aspects 
of lung development and pathophysiology, the intracellular AIMP1 and its underlying 
molecular mechanism(s) has not. 
With its localization at the epithelial-mesenchymal interface, AIMP1 may 
regulate sacculogenesis; disruption of the expression of AIMP1 may hinder proper lung 
development. The study presented here utilized an exon-deletion model that was 
generated on a C57BL/6 background to test the hypothesis that Aimp1 regulates lung 
development. Ablation of AIMP1 led to neonatal lethality and abnormal epithelial cell 
organization of both bronchiolar and alveolar regions. Having verified the localization of 
AIMP1 to the cell membrane, we found that AIMP1 interacted with various 
phosphoinositides. F-actin deposition was disrupted in fibroblasts from Aimp1 -/- mice , 
suggesting that AIMP1 plays a role in F-actin remodeling, a necessary feature for 
sacculogenesis and alveolarization. Together, these results suggest AIMP1 critically 




All animal studies complied with the animal protocols approved by the Indiana 
University Institutional Animal Care and Use Committee. We generated and verified 
AIMP1 -/- mutant mice as described in detail in the online supplement. 
 
Generation of AIMP1 Knockout Mice 
C57BL/6 mice were obtained from Jackson Laboratories. Studies using mice were 
performed according to the animal protocols approved by the Indiana University 
Institutional Animal Care and Use Committee. The UTSW Transgenic Mouse Core 
generated the AIMP1 -/- (AIMP1 KO) mice. Mouse embryonic stem (ES) cells were 
selected after transfection using electroporation with AIMP1 targeting vector, in which 
one loxP site and Frt sites contained neomycin resistance gene cassette were introduced 
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into intron 1 of AIMP1 gene, one loxP site was introduced into intron 2 of AIMP1 gene. 
ES stable clones were identified using Southern blotting and PCR sequencing analysis, 
and then were injected into blastocysts harvested from C57BL/6 mice. Chimeric founder 
mated with C57BL/6 female mice and created F1 offspring. F1 female mice mated with 
FLP transgenic male mice to create F2 mice carrying heterozygous floxed AIMP1 and 
FLP. Mating of female and male F2 created homozygous floxed AIMP1 F3 mice. Mating 
of female F2 with CAG-Cre transgenic mice generated heterozygous AIMP1 KO and 
CAG-Cre F3 mice. Mating these two types of F3 mice generate homozygous AIMP1 KO 
mice expressing Cre. 
 
Cell lines and reagents 
HEK293 and MDCK cell lines were obtained from ATCC and cultured in DMEM 
containing 10% fetal bovine serum (Seradigm), 1X Glutamax (Invitrogen), and 1X 
penicillin/streptavidin (Invitrogen). Cells were passaged below 80% confluency or 
harvested as indicated in the experiments. 
 
Recombinant AIMP1 preparation 
6x-His tagged EMAP II was prepared as previously described33. Endotoxin concentration 
in samples was <0.1 EU/mL as determined by LAL assay (88282, Pierce). 
 
Transmission Electron Microscopy 
The lung specimens were fixed in 3% Glutaraldehyde/0.1M phosphate buffer. After 
primary fixation the specimens were rinsed with phosphate buffered saline (PBS) 
followed by post fixation with 1% osmium tetroxide in phosphate buffer for one hour. 
After rinsing again with PBS the tissue specimens were dehydrated through a series of 
graded ethyl alcohols from 70 to 100%. After dehydration the specimens were infiltrated 
with 2 changes of 100% acetone and a 50:50 mixture of acetone and embedding resin 
(Embed 812, Electron Microscopy Sciences, Hatfield, PA) for over the weekend. 
Specimen vial lids were popped and acetone allowed to evaporate off for 3 hours. Then 
specimens were embedded in a fresh change of 100% embedding media. Following 
polymerization overnight at 60°C the blocks were then ready to section. Thin sections 
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were cut (80-90nm), stained with UA replacement stain, (Electron Microscopy Sciences, 
Hatfield, PA) then viewed on a Tecnai Spirit (ThermoFisher, Hillsboro, OR) with digital 
images taken with an AMT (Advanced Microscope Techniques, Danvers, MA) CCD 
camera. 
 
Wet-to-dry lung weight ratios 
Lungs were removed surgically from pups on day 0, weighed, recorded as the wet 
weight, and then dried at 65 degrees Celsius for 48 hours. The ratio was then calculated 
by dividing the wet with the dry weight. 
 
Immunoblotting 
Sections of the right lung were placed in tubes containing modified lysis buffer. The 
tubes were then placed and homogenized in Bullet Blender Storm (BBY24M, Next 
Advance Inc.). Protein concentrations were determined by Bradford reagent (Bio-Rad). 
Twenty micrograms of lung tissue homogenates were loaded into NuPage Novex 4-12% 
Bis-Tris Protein gels (Invitrogen), incubated in 20% ethanol for 5 minutes, and 
transferred onto nitrocellulose membranes using iBlot v2 (Invitrogen). The membranes 
were placed in 5% blocking buffer (BioRad) in tris-buffered saline with 0.05% Tween-20 
for 1 hour at room temperature. Membranes were incubated overnight at 4 oC in primary 
antibodies listed in Supplementary Table. 
 
Lung Tissue Immunofluorescence and Morphometry Analysis 
Lung tissue sections were prepared as previously described with slight modifications 94. 
Antigens on lung sections of five microns were retrieved and stained with antibodies 
according to Supplementary Table. 
   
Biotinylation 
After being grown to near confluency, HEK293 and MDCK cells were used for 





Lipid Overlay Assay  
Putative interactions of recombinant AIMP1 and membrane lipids were performed 
according to manufacturer’s instructions (Membrane Lipid Strips, Echelon Biosciences). 
 
5.3 Results 
Aimp1 gene targeting, confirmation, and verification of null allele. To determine the 
role of Aimp1 in development, we generated mice with a conditional floxed allele of the 
Aimp1 gene to enable targeted deletion. The targeting vector was designed to allow for 
the loxP-mediated deletion of exon 2 of the Aimp1 gene. The CMV-Cre genetic driver 
was used to generate a whole-body knockout of Aimp1 in mice following the removal of 
the selection cassette. There was a global loss of Aimp1 following homologous 
recombination (Figure 5.1A). Genomic PCR obtained from tail samples confirmed 
recombination of the floxed Aimp1 allelle (Figure 5.1B,C). Immunoblotting established 
the loss of Aimp1 protein in lungs of knockout mice compared to littermate wildtype 
(AIMP1 WT) (Figure 5.1D). Heterozygous mice (Aimp1+/-) were fertile and viable; they 
were further mated and their litters recorded. By the time neonatal progeny of the 
heterozygous mice were weaned, however, homozygous null Aimp1-deficient or 
knockout (Aimp1-/-) mice were not recovered. This suggested that Aimp1 could impact 
murine development.  
 
Homozygous null Aimp1 mutation in mice causes neonatal lethality. Heterozygous 
mice were mated and sacrificed at various time points through development. Genotypes 
of progeny were recorded at embryonic days 14.5 (E14.5), 18.5 (E18.5), and day of birth 
(D0). Observed Mendelian ratios, 1:2.44:1.05, 1:3.1:1.89, 1:2.7:1.5, respectively, 
throughout mouse development were not significantly different from expected Mendelian 
ratios (Table 5.1). These observations suggest that Aimp1 deficiency is not lethal during 
embryogenesis and follows Mendelian genetics. 
 
AIMP1 deletion leads to a respiratory distress phenotype with impaired 
sacculogenesis. Preceding day of birth, mice were viable. However, D0 knockout mice 
appeared mildly cyanotic and died within 24 hours, suggesting that these mice suffered 
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from respiratory distress (Figure 5.2A). Analysis of Mendelian ratios of knockout to 
wildtype mice at the time of weaning supported neonatal lethality (Table 2). Gross 
morphology of the excised cardiothoracic lung blocks revealed mild distal alveolar 
dysplasia at the distal edges (Figure 5.2B). Although AIMP1 did not lethally affect 
embryogenesis, it could play a role in determining other aspects of lung development. 
Therefore, lungs at E14.5 and D0, during canalicular and saccular stages, were examined. 
Histologic analysis did not reveal any differences between genotypes in E14.5 (Figure 
5.2C).  
However, at both D0 and E18.5, an earlier time point in sacculogenesis, lung and 
body weights were significantly decreased (Table 5.3). In the knockout mice, lungs were 
dysplastic as determined by H & E staining (Figure 5.2C, right column). The bronchioles 
of the forming respiratory tubules in wildtype lungs were singly layered of columnar or 
cuboidal epithelial cells (Figure 5.2C, middle column). In contrast to the organized 
epithelium in WT mice, in D0 KO lungs, the epithelium was disorganized and its nuclei 
positioned at various levels, similar to that observed in the normal pseudostratified 
epithelium of the pseudoglandular stage (Figure 5.2C). Supporting the disorganization as 
observed in H & E, immunofluorescence of E18.5 lungs revealed that E-cadherin 
expression was no longer restricted to the lateral membrane between epithelial cells in 
knockout mice (Figure 5.2D). Rather it was observed in the apical membrane as well. 
Furthermore, CCSP expression was expressed in close proximity in distal epithelium of 
lungs of knockout but not in wildtype mice (Figure 5.2E). These results suggest that 
Aimp1 regulates the organization of epithelial cells during sacculogenesis. 
 
Characterization of alveolar epithelial cells in knockout mice. It is possible that 
because of improper epithelial cell organization, lungs of knockout mice are leaky, 
incapable of clearing fluid upon birth, and as a result become cyanotic. To test this 
possibility, wet-to-dry ratios of lungs excised from wildtype and knockout mice were 
compared at D0. There was an insignificant difference between the ratios suggesting that 
there was a lack of difference in lung inflation upon the day of birth (Figure 5.3A). 
Similarly, lungs from both knockout and wildtype mice remained buoyant in lung 
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flotation tests at D0 (data not shown). Together, these results suggest that lungs in Aimp1 
-/- mice can properly inflate and do not suffer from pulmonary edema. 
If lungs can properly inflate, then surfactant deficiencies or abnormalities are 
unlikely. To test this, by immunoblotting, there was no significant change in total 
surfactant protein C levels that were measured in D0 lung homogenates (Figure 5.3B). 
Similarly, immunofluorescence and transmission electron microscopy revealed no 
significant defects in differentiation or cells containing lamellar bodies, respectively 
(Figure 5.3C, D). These results suggest that Type II cell differentiation was not 
significantly altered. 
Although Type II cellular differentiation was comparable between AIMP1 +/+ 
and -/- mice, Type I was not. Lungs of knockout mice had significantly decreased Type I 
cell marker Aquaporin 5 (AQP5) protein levels compared to D0 littermate controls as 
measured by immunoblotting (Figure 5.3E). The deficiency in Type I cells was traced 
back to E18.5 when immunofluorescence of another Type I marker, podoplanin (PDPN) 
also showed a significant decrease in expression in knockout mice (Figure 5.3F).  
 
Adherens Junctions in knockout mice are disorganized. Establishment of the 
epithelial cell-cell contacts is crucial to development. With the observed disorganization 
and deficiency in Type I, we postulated that adherens junctions (AJ) in knockout mice 
might be disrupted. Immunoblotting for markers of AJ in addition to E-cadherin, beta-
catenin and P120 in D0 mice showed no significant differences between genotype (Figure 
5.4A, B). Despite insignificant differences in protein expression, there was aberrant 
localization in knockout lungs as evidenced in immunofluorescence of AJ (Figure 5.4C). 
 
AIMP1 localizes to the actin cytoskeleton-plasma membrane interface. Whereas in 
some reports AIMP1 is described to remain cytoplasmic, we and others previously 
reported that AIMP1 localizes to the cellular membrane, coinciding with its expression in 
tissue at the epithelial-mesenchymal interface. Immunofluorescence using an antibody 
against AIMP1 shows a portion that co-localizes with phalloidin, a stain for F-actin 
(Figure 5.5A). Complementing the immunofluorescence, biotinylation of cell-surface 
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bound proteins followed by immunoblotting show a portion of AIMP1 localizes to the 
outer membrane (Figure 5.5B). 
AIMP1 lacks a domain classically known to interact with the membrane. 
However, with advanced technological approaches, domain prediction analysis suggests 
that AIMP1 contains an intrinsically disordered region95. Therefore, it is plausible that 
AIMP1 can directly with the membrane by way of the region. We tested this by using 
recombinant AIMP1 on lipid overlay assays and found that it could bind to 
phosphoinositides, such as phosphatidylinositol 3,4-bisphosphate, phosphatidylinositol 
3,5-bisphosphate, and phosphatidylinositol 4,5-bisphosphate (Figure 5.5C). The 
identified phosphoinositides have all been shown to play a role in cytoskeletal dynamics. 
Mouse embryonic fibroblasts isolated from wildtype or knockout mice at E14.5 
were cultured and analyzed for their F-actin structure. Immunofluorescence showed 
several impairments in F-actin deposition and adhesion points of contact in knockout 
MEF’s (Figure 5.5D, E). These results suggest that at least a portion of AIMP1 localizes 




This study was to examine the role of intracellular AIMP1 during murine lung 
development. Mechanisms of the transitions from canalicular to alveolar stages are 
poorly understood. Particularly in the lung, its morphology during development dictates 
the later function and phenotype. The data presented in this study suggests that AIMP1 
plays a crucial role in lung development through its regulation of epithelial cellular 
organization and interaction with the lipid membrane. 
The generated AIMP1 knockout mutation described in this study was lethal on the 
day of birth. A recent study identified components of the tRNA synthetase complex to be 
essential in the human genome, but AIMP1 was not38. Given that the gene AIMP1 is 
highly conserved across organisms, its functionality as a scaffold of the multi-synthetase 
complex might be redundant, and alternative functions in mammals may have emerged, 
i.e., a moonlighting function19,96-98. Supporting this notion, disruption of AIMP1 does not 
seem to significantly alter bulk protein translation37; similar results were found when 
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utilizing SunSET (data not shown). Therefore an insufficiency in global protein 
translation seems unlikely to account for the lethal phenotype in this study.  
Characterization of the lungs of AIMP1 knockout mice revealed an insufficiency 
of Type I but not Type II cells. During sacculogenesis, a bipotent progenitor cell 
population differentiates independently into Aqp5+ Type I and Sftpc+ Type II cells, which 
both mature into alveologenesis6. Early events such as lung bud formation or branching 
in the stages preceding the saccular stage were not more thoroughly investigated. 
Examination of lungs at the canalicular E14.5 stages revealed no gross abnormalities; 
only until E18.5 was epithelial cell disorganization significant. This makes it less likely 
that there were defects in branching morphogenesis. Rather these experiments suggest 
AIMP1 to mediate differentiation of the bipotent progenitor cell population into Type I 
cells beginning in sacculogenesis. 
Notably, the phenotypes of the AIMP1 knockout mouse subtly resemble the 
Crumbs3 knockout mice, further supporting a role for AIMP1 in epithelial cell 
development99. These resembling phenotypes suggest AIMP1 could impact epithelial 
polarity. AIMP1 localizes to the epithelial-mesenchymal interface within lungs27,29. 
Within the cell, its expression was at the actin cytoskeleton membrane, consistent with 
other proteins that contain intrinsically disordered proteins and interact with 
phosphoinositides. Improper F-actin deposition was found in MEFs lacking AIMP1. 
Although it is currently unknown how F-actin might impact epithelial differentiation in 
the developing lung, it is essential in other contexts. AIMP1 may possibly regulate the F-
actin dynamics, and in turn impact epithelial cell organization and Type I cell 
differentiation. 
This study shows that although AIMP1 is not essential for embryogenesis, it is for 
proper lung development. AIMP1 regulates the epithelial cellular organization through F-
actin dynamics, and in turn, reduces the Type I cell differentiation. Further studies of 
AIMP1 on the development of organ systems, as well as a deeper understanding of the 
mechanisms may uncover other alternative moonlighting functions.  
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5.5 Figures and Tables 
 
 
Figure 5.1. Generation of the Aimp1 knockout mice. (A) Schematic of the Aimp1 targeting 
construct used to generate knockout mice. Upper diagram illustrates the genomic structure 
of the Aimp1 locus. Following homologous recombination as indicated by the dashed 
lines, the lower diagram indicates the NEO selection cassette. (B) Genomic DNA from 
wild-type and Aimp1 heterozygous mice were digested with the restriction enzyme Bgl2 
and probed with a 32P-labeled 5’ probe. The correctly sized bands on the Southern blot 
(i.e., 8.6 kb for the wild-type allele, 7.5 kb for the mutant allele) confirmed the 
homologous recombination event. Mut: mutant allele, Wt: wildtype allele. (C) 
Representative genotyping gel of genomic DNA obtained from tails of wildtype (+/+), 
heterozygous (+/-), knockout (-/-) mice. (D) Representative immunoblot probed for 






  Genotype 
  +/+ +/- -/- 
E14 Observed 19 44 18 
 Expected 20.25 40.5 20.5 
     
E18.5 Observed 17 28 9 
 Expected 13.5 27 13.5 
     
D0 Observed 23 62 34 
 Expected 29.75 59.5 29.75 
     
Table 5.1. Observed counts of progeny obtained from heterozygous mice 
crossed over period of gestation. Chi-square test was used to evaluate if 
observed counts were not significantly different from expected at all ages. 
  
  Genotype 
  +/+ +/- -/- 
D28 Observed 28 58 0 
 Expected 21.25 43 21.25 
     
Table 5.2. Observed counts of progeny obtained from heterozygous cross at the 
time of weaning. Chi-square test was used to evaluate if observed counts were 







Figure 5.2. Respiratory distress phenotype of mice lacking Aimp1. (A) Representative picture of newborn 
pups from genotypes. Knockout mice present with cyanosis. (B) Representative picture of cardiothoracic 
block. Arrows point to distal edges where alveoli are dysplastic in -/-. (C) Hematoxylin and eosin (H & E) 
stains of lungs obtained from embryonic 14.5, and newborn, (D0) mice. (D) Representative 
immunofluorescent image of E-cadherin outlining the distal alveolar or bronchiolar epithelium of +/+ or -/- 







Figure 5.3. Characterization of the alveolar epithelial cells in knockout mice. (A) Wet:dry ratios of lungs 
at day of birth, n = 11, 8, respectively. (B) Non-significant difference in protein expression of Surfactant 
Protein C, SFTPC, type II cell marker. Representative immunoblot, ACTB (loading control). (C) 
Comparable expression and location of SFTPC positive cells in both genotypes. (D) Representative 
transmission electron microscopy showing comparable alveolar epithelium, including those containing 
lamellar bodies and glycogen. (E) Protein expression of Aquaporin 5, AQP5, Type I cell marker, in D0 
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whole lung homogenates. Representative immunoblot probed for AQP5. ** p-value ≤ 0.05, n = 3 per 
genotype. (F) Representative immunofluorescent image of podoplanin, Type I cell marker at E18.5. 
 
 
Figure 5.4. Assessing the integrity of adherens junction in knockout mice. (A) Non-significant difference 
in protein expression of β-catenin, Ctnnb1, compared to Actb (loading control). (B) Non-significant 
difference in protein expression of p120, Ctnnd1, compared to Actb (loading control). (C) Representative 






 Genotype +/- -/- +/+ 
E18.5     
 Body Weight (mg) ± SEM 1048.6 ± 32 928.7 ± 49** 1106.9 ± 47 
 Lung Weight (mg) ± SEM 34.3 ± 1.2 28.1 ± 2** 38.8 ± 3.8 
 Lung (mg)/Body (g) ± SEM 32.9 ± 0.5 32.1 ± 1.4 35.6 ± 0.09 
D0     
 Body Weight (mg) ± SEM 1354.8 ± 27.1 1133.8 ± 26.6** 1364.9 ± 48.7 
 Lung Weight (mg) ± SEM 35.6 ± 1.1 34.4 ± 1.6 35.8 ± 2.4 
 Lung (mg)/Body (g) ± SEM 26.4 ± 0.6 29.8 ± 1.1** 25.9 ± 1.3 
     
Table 5.3. Body weights and lung weights of progeny from cross between heterozygous Aimp1 +/- 
mice. For E18.5, n = 23, 14, 8; for D0, n = 50, 27, 19, respectively. **p-value ≤ 0.01, Tukey’s post-







Figure 5.5. A fraction of AIMP1 resides at the actin cytoskeletal membrane interface. (A) 
Immunofluorescence of AIMP1, Phalloidin in HEK293 cells grown to confluency. AIMP1 is 
expressed at the membrane, and arrows point to co-localization of AIMP1 and Phalloidin. (B) 
Representative immunoblot of biotinylated proteins obtained from cell surface-bound proteins in 
MDCK and HEK293 cells. (C) Lipid overlay assay to indcate which membrane lipids interact with 





Chapter 6: Concluding Remarks and Future Direction 
 The work presented in this thesis details the mechanisms of a moonlighting 
protein in lung development and BPD. While the murine model of BPD was established, 
a quantitative PCR robust workflow is adapted to reconcile several conflicting reports 
regarding a key signaling angiogenic factor Vegf-a (Chapter 2) and used in subsequent 
studies to measure transcription levels.  
 The studies on the effects of EMAP II in the BPD model are integrative as they 
measured not only traditional outcomes such as morphometric analysis and inflammation 
but also pulmonary function testing (Chapter 3). It is noteworthy to discuss the following 
from Chapter 3: (1) EMAP II recruits galectin-3+ macrophages during BPD pathogenesis; 
and (2) utilizing male mice. At the time of completing Chapter 3, the origin, regenerative 
potential, and heterogeneity of macrophage populations within a specific organ including 
the lung was unclear. A recent surge of studies regarding the populations has identified 
three main sub-populations in the lung under homeostatic conditions100,101. Two of the 
three are the alveolar macrophage (AM) and “primitive” interstitial macrophage (pIM) 
derive from the fetal liver and yolk sac, respectively; the third is the “definitive” 
interstitial macrophage (dIM) that derive from circulating bone-marrow derived 
monocytes and replace the pIM over time. Under normal developmental conditions in 
mice, the three populations appear in waves over time. In neonates, galectin-3 is 
predominantly expressed on interstitial macrophages at birth but predominantly in AM at 
postnatal day 6101. Macrophages in the lung can maintain their populations independently 
of circulating precursors in homeostasis, but others are recruited from the bone marrow in 
pathologic conditions. In the pathogenesis of BPD, it is not known what subpopulations 
exist.  
In light of the results from Chapter 3, these recent studies argue for investigation 
into the identity and regenerative potential of macrophage subpopulations recruited by 
EMAP II. Its expression at the epithelial-mesenchymal interface may allow for the 
moonlighting properties of EMAP II to be a signal for monocyte/macrophage recruitment 
between the alveoli and lumen. This work will be useful not only to understand the role 
of EMAP II in context of macrophage biology during normal lung development, but also 
a population to target BPD pathogenesis. 
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The pulmonary functional testing in Chapter 3 is performed on gender-matched 
male to avoid the effects of estrogen as a confounding variable. Males among preterm 
infants diagnosed with BPD have higher morbidities and associated risks than do their 
female counterparts102,103. This is possibly due to differences in estrogen levels between 
males and females104. Estrogen found in females is needed for alveolar formation and 
their proper size in rodent models. This suggests that estrogen replacement therapy may 
lower BPD incidence. The only known-to-date randomized controlled clinical trial 
utilizing the replacement therapy did not demonstrate significant difference in either 
incidence of BPD or morbidity105. The clinical trial did contain many limitations 
including, but not limited to, low sample sizes. It remains unclear whether the 
replacement therapy is viable against BPD incidence, particularly in very low birth 
weight infants. Estrogen effects also confound studies on the association of pulmonary 
hypertension with BPD. Large discrepancies exist in the results of studies regarding the 
effect of estrogen; confounding discrepancies occur partly due to conflicting results in 
animal models compared to that found in human models106.  
The neutralization of EMAP II rescues mice from BPD outcomes including 
secondary pulmonary hypertension. This raises new questions. One of which was the 
signaling mechanism(s) that occurred in those macrophages recruited by EMAP II.  
 The transcription profile activated by EMAP II was unique and unexpected 
considering several pieces of evidence that suggest it to primarily serve a pro-
inflammatory role (Chapter 4). Yet activation of JAK/STAT signaling in the context of 
macrophage polarization is generally anti-inflammatory. The dynamic bimodal phase of 
transcription activation further reinforce the spatiotemporal regulation performed by 
EMAP II that can be seen in several contexts. Further studies remain to explore the time-
dependent and context-specific transcriptional complex formations that may occur upon 
exposure to EMAP II in macrophages and other subsets of the lung. 
While many experiments demonstrate the physiological effects of EMAP II, they 
also highlight how little was known about the intracellular AIMP1. The discovery of the 
moonlighting function and its impact on epithelial cell organization through the 
regulation of F-actin dynamics is not expected (Chapter 5). Other phenotypes were 
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present in the knockout mice in line with a disruption to epithelial cell organization. The 
knockout mice born were cyanotic and succumbed to respiratory distress. 
The impact of AIMP1 on F-actin deposition found in vitro argue for future studies 
that delineate the in vivo contribution of AIMP1 to lung development and BPD. It 
remains to be explored the impact of the various protein domains of AIMP1. This may be 
possible using models of cell-specific deletions to circumvent the neonatal lethal 
phenotype remain to be explored. In particular, as F-actin dynamics are crucial to the 
ability of macrophages to serve their physiological role in phagocytosis, a key future 
study would be to determine if there is a role for intracellular AIMP1 in innate immunity.  
 
6.1 Clinical Implications 
Despite recent clinical trials and therapeutic attempts against its pathogenesis, 
BPD remains the leading sequelae among prematurely born infants. Yet few therapies 
such as caffeine or vitamin A have been shown to lower the incidence of BPD. Their 
protective effects have been primarily attributed to lowering pulmonary inflammation at 
the onset of mechanical ventilation or oxygen therapy. This has spurned several studies to 
target inflammation in BPD pathogenesis and its link with disrupting pulmonary function. 
However, targeting inflammatory mediators such as TNF-alpha has been unsuccessful, 
leaving a factor that initiates inflammatory mediators to be discovered. 
Several pathologies, including BPD, are linked with elevated EMAP II levels. The 
experiments in this thesis provide evidence that EMAP II is not only elevated at the time 
of BPD but also initiated early in its pathogenesis (Chapter 3). This presents a 
translational need to test whether elevated EMAP II levels can be an early diagnostic 
marker of BPD. A future study would be needed to correlate EMAP II levels with human 
BPD outcomes including secondary pulmonary hypertension at the onset of ventilation in 
human tracheal aspirates, distinguishing it from other potential biomarkers at onset of 
BPD; translated from the mouse model, it is possible that increased EMAP II levels in 
patients diagnosed with BPD may also have worsened pulmonary function outcomes later 
in life. This may be due to downstream inflammation caused by unknown subsets of 
macrophages. Those macrophages recruited by EMAP II were hypothesized to have a 
pro-inflammatory, activated state. However, evidence suggests that it is not simply 
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inflammatory (Chapter 4). Contrary to the hypothesis, the study reveals a transcriptional 
subset unique from traditionally classified M1 or M2 macrophages and is driven in part 
by STAT3, a transcription factor whose physiological function is highly context driven. 
Future studies are warranted, which would distinguish EMAP II-recruited macrophages 
and compared to those subsets activated by traditionally identified mediators such as 
TNF-alpha, although some overlap is to be expected. Recent studies do indicate that the 
galectin-3 expressing macrophages recruited by EMAP II also are the same macrophage 
subset recruited in other lung pathophysiological processes such as pulmonary fibrosis 
107. This may represent a potential macrophage subset to target against the pathogenesis 
of BPD. 
 
6.2 Concluding remarks 
 EMAP II/AIMP1 has been associated with lung pathologies such as 
bronchopulmonary dysplasia (BPD) with unclear moonlighting mechanisms. This thesis 
delineates the mechanisms, which will allow for better, effective targeting of the protein 
to limit BPD. The work highlights the physiological roles of the protein serving through 
newly found moonlighting mechanisms, particularly in macrophages, in the context of 
lung development and pathogenesis in BPD. The workflow, employed in this thesis and 
future studies too, makes it possible for robust quantification of gene expression analysis 
in studies of lung development. Increases in macrophages accompany the BPD phenotype 
due to sustained and elevated EMAP II, which suggest in vivo future studies of the 
macrophage subsets. The unusual, mixed transcriptional profile of recruited macrophages 
exposed to EMAP II reinforces the basis for future studies of macrophage subsets. 
Clearly EMAP II plays an important role on macrophage biology. The full-length 
precursor AIMP1 impacts the proper development of the epithelium of a lung in relation 
to its composition and functional structure. Understanding the mechanisms may aid in 
guiding future therapeutic studies against pulmonary pathogenesis. Collectively, these 
findings demonstrate a critical role of the moonlighting protein AIMP1 in both lung 
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